首頁 > 市場調查報告書 > 製藥

基因治療學和RNAi 以基因為基之藥物開發

全球表觀遺傳學市場：依產品、服務、技術、方法、應用、最終用戶和地區分類－預測至2031年

市場調查報告書

商品編碼

2076882

全球表觀遺傳學市場：依產品、服務、技術、方法、應用、最終用戶和地區分類－預測至2031年

Epigenetics Market by Product (Kit, Enzyme), Service (Single-Cell Epigenomics, Multi-omics), Method (DNA Methylation, Histone Modification), Technique (NGS, PCR, MS), Application (Oncology, Immunology, CVD) - Global Forecast to 2031

出版日期: 2026年06月26日 | 出版商:

MarketsandMarkets | 英文 555 Pages | 訂單完成後即時交付

價格

簡介目錄圖表

預計表觀遺傳學市場將從 2026 年的 22.2 億美元成長到 2031 年的 39.2 億美元，預測期內複合年成長率為 12.0%。

預計在預測期內，該市場將保持穩定成長，這主要得益於表觀遺傳學分析在腫瘤學研究、精準醫療、藥物發現、生物標記檢驗和轉化研究中日益廣泛的應用。次世代定序、PCR和qPCR、質譜分析、基於超音波處理的染色質製備以及甲基化晶片等技術能夠分析DNA甲基化、組蛋白修飾、染色質可及性、非編碼RNA和染色質重塑。這些工具可應用於癌症診斷、治療標靶識別、疾病分類、治療反應監測、發育生物學、免疫學、神經科學和代謝性疾病研究等眾多領域。

調查範圍
調查期	2026-2031
基準年	2025
預測期	2026-2031
計算單位	金額（10億美元）
部分	按產品、服務、技術、方法、應用程式、最終用戶、地區
目標區域	北美洲、歐洲、亞太地區、拉丁美洲、中東和非洲

基於液態生物檢體、單細胞表觀基因、多組體學整合和人工智慧數據分析的甲基化生物標記的應用日益廣泛，推動了製藥、生物技術、學術界、臨床和合約研究組織（CRO）等行業的進一步普及。此外，對標準化試劑盒、高品質抗體、定序試劑、酵素、自動化樣品製備方案和生物資訊平台的需求不斷成長，提高了工作流程的可重複性和數據可靠性。然而，高昂的定序和分析成本、複雜的數據解讀、抗體表現的差異性以及表觀遺傳學工作流程標準化的難度，仍然限制市場成長。

“預計在預測期內，DNA甲基化領域將以最高的複合年成長率成長。”

由於DNA甲基化在癌症檢測、生物標記發現、疾病分類和治療反應監測等領域的應用日益廣泛，預計將在表觀遺傳學市場中以最高的複合年成長率成長。 DNA甲基化檢測被廣泛用於研究啟動子甲基化、基因靜默、表觀遺傳老化、腫瘤譜分析以及基於液態生物檢體的診斷。基於亞硫酸氫定序、甲基化特異性PCR、甲基化晶片和NGS（次世代定序）的甲基化譜分析技術的日益普及，正在推動藥物研發、臨床檢查室和轉化研究領域的需求成長。

“次世代定序領域佔據最大的市場佔有率。”

次世代定序(NGS) 技術憑藉其高通量、全基因組的表觀遺傳調控資訊獲取能力，佔據了表觀遺傳學市場最大的佔有率。 NGS 廣泛應用於 DNA 甲基化譜分析、ChIP-seq、ATAC-seq、染色質可及性研究和單細胞表觀基因領域。其在腫瘤學研究、生物標記發現、藥物研發和精準醫療領域的廣泛應用，進一步鞏固了其主導地位。對更精細的表觀基因覆蓋、可擴展的分析以及與多體學工作流程整合的需求不斷成長，持續推動著基於 NGS 的表觀遺傳學解決方案的發展。

“預計美國在預測期內將以最高的複合年成長率成長。”

由於美國擁有強大的定序、分子生物學、診斷和生物資訊公司網路、先進的研究基礎設施以及表觀表觀基因技術在研究和臨床領域的高應用率，預計美國將在表觀遺傳學市場實現最高的複合年成長率。表觀遺傳學在腫瘤學、精準醫療、藥物研發、液態生物檢體開發和生物標記檢驗等領域的日益廣泛應用正在推動市場成長。次世代定序、PCR和qPCR、甲基化晶片、ChIP-seq、ATAC-seq和單細胞表觀基因等技術已被製藥公司、生物技術公司、學術機構、合約研究組織（CRO）和臨床檢查室廣泛應用。

提供表觀遺傳學相關產品和服務的領導公司包括：賽默飛世爾科技公司（美國）、默克集團（德國）、Illumina公司（美國）、PacBio公司（美國）、丹納赫公司（美國）、Bio-Rad Laboratories公司（美國）、Active Motif公司（美國）、新英格蘭生物實驗室（美國）、英國生物實驗室（美國公司） Diagenode公司（美國）、羅氏公司（瑞士）、Promega公司（美國）、EpigenTek集團公司（美國）、EpiCypher公司（英國）、Fios Genomics公司（英國）、GenomeScan公司（荷蘭）、Creative Biogene公司（美國）、BPS Bioscience（美國）、Abnova（美國）、Creative Biogeneptics）、BPS Bio年（美國）、Abnovanative）。 Genomics公司（美國）和諾禾致源公司（中國）。

調查範圍

本研究報告分析了表觀遺傳學市場，包括產品和服務、產品（試劑盒和試劑{抗體、分離萃取試劑盒和試劑、ChIP定序盒和試劑、亞硫酸氫鹽轉化試劑盒和試劑、全基因組擴增試劑盒和試劑、切割/標記試劑盒和試劑、5-hmC和5-mC分析試劑盒和試劑、組蛋白、其他試劑盒和試劑}、酶{DNA聚合酵素、DNA連接酶、Tn5轉座酶、轉化酶[TET和APOBEC]、蛋白質修飾酶、其他酶}以及儀器和配件）和服務（DNA甲基化譜分析服務、染色質譜分析服務、染色質可及性譜分析服務）。該市場按服務（單細胞表觀基因服務、多體學服務和其他服務）和技術（次世代定序、PCR和qPCR、質譜分析）進行細分。超音波和其他技術）、方法（DNA甲基化、組蛋白修飾和其他方法）、應用領域（腫瘤學、代謝性疾病、免疫學、發育生物學、心血管疾病、人群篩檢和其他應用領域）、按最終用戶分類的產品市場（學術和研究機構、製藥和生物技術公司、醫院和診所以及受託研究機構）、按最終用戶分類的服務市場（製藥和生物技術公司、學術和研究機構、醫院和診所以及受託研究機構）以及地區（北美、歐洲、亞太地區、拉丁美洲、中東和非洲）。

本報告詳細介紹了影響表觀遺傳學市場成長的關鍵因素，例如促進因素、阻礙因素、挑戰和機會。該報告對主要行業參與企業進行了全面分析，深入剖析了他們的業務概況、產品系列、關鍵策略、新產品發布、收購以及與表觀遺傳學市場相關的最新發展。此外，報告也對表觀遺傳學產業生態系統中新興的新創公司進行了競爭分析。

購買本報告的主要好處

本報告透過提供整體市場及其細分市場的收入預測，幫助市場領導者和新參與企業。它還有助於相關人員更深入了解競爭格局，有效地進行業務定位，並制定合適的打入市場策略。透過本報告，相關人員可以掌握市場趨勢，並獲取有關關鍵市場促進因素、限制因素、機會和挑戰的資訊。

本報告深入分析了以下幾點：

關鍵促進因素（定序成本和時間的降低、對人群篩檢計劃的日益重視、表觀遺傳學研究的技術進步以及對錶觀遺傳藥物和基於表觀遺傳學的療法的需求不斷成長）、限制因素（表觀表觀基因數據在毒理學中的應用有限、數據隱私問題和安全問題）、阻礙因素觀察相關的遺傳應用、體學數據在毒理學中的遺傳問題的整合性影響（表觀遺傳學的挑戰）、對錶觀的遺傳應用、對特徵
產品開發/創新：對錶觀遺傳學市場的新產品發布和創新進行詳細分析。
市場開發：提供各地區盈利市場的全面資訊及市場分析。
市場多元化：全面介紹表觀遺傳學市場的新產品、未開發的市場、近期趨勢和投資狀況。
競爭評估：對錶觀遺傳學市場主要參與者的市場佔有率、成長策略和產品/服務進行詳細評估，包括 Thermo Fisher Scientific Inc.（美國）、Merck KGaA（德國）、Illumina, Inc.（美國）、PacBio（美國）、Danaher Corporation（美國）、Bio-Rad Laboratories, Inc.（美國）、Active Motiland, Inc. Biolabs（美國）、QIAGEN（荷蘭）、Zymo Research Corporation（美國）和 Revvity（美國）。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 義大利
- 西班牙
- 其他
亞太地區
- 中國
- 日本
- 印度
- 澳洲
- 韓國
- 其他
拉丁美洲
- 巴西
- 墨西哥
- 其他
中東
- 海灣合作理事會國家
- 其他
非洲
- 發現人群特異性生物標記以促進生長和以疾病為重點的甲基化研究。

第18章競爭格局

主要參與企業的策略/優勢，2023年1月至2026年5月
收入分析
2025年市佔率分析
企業估值矩陣：主要公司，2025 年
公司估值矩陣：新創企業/中小企業，2025 年
企業估值和財務指標
品牌對比
競爭格局

第19章：公司簡介

主要參與企業
- THERMO FISHER SCIENTIFIC INC.
- ILLUMINA, INC.
- MERCK KGAA
- DANAHER CORPORATION
- BIO-RAD LABORATORIES, INC.
- REVVITY
- PACBIO
- ACTIVE MOTIF, INC.
- NEW ENGLAND BIOLABS
- QIAGEN
- ZYMO RESEARCH CORPORATION
- HOLOGIC DIAGENODE
- F. HOFFMANN-LA ROCHE LTD.
- PROMEGA CORPORATION
- EPIGENTEK GROUP INC.
其他公司
- EPICYPHER
- FIOS GENOMICS
- GENOMESCAN
- CREATIVE BIOGENE
- BPS BIOSCIENCE, INC.
- ABNOVA CORPORATION
- CREATIVE DIAGNOSTICS
- BIOMODAL
- 10X GENOMICS
- NOVOGENE CO., LTD.

第20章：調查方法

第21章附錄

簡介目錄圖表

Product Code: BT 2775

The epigenetics market is expected to reach USD 3.92 billion in 2031 from USD 2.22 billion in 2026, at a CAGR of 12.0% during the forecast period. The market is expected to grow steadily during the forecast period, driven by increasing use of epigenetic analysis in oncology research, precision medicine, drug discovery, biomarker validation, and translational studies. Technologies such as next-generation sequencing, PCR & qPCR, mass spectrometry, sonication-based chromatin preparation, and methylation arrays enable the analysis of DNA methylation, histone modifications, chromatin accessibility, non-coding RNAs, and chromatin remodeling. These tools support applications across cancer diagnostics, therapeutic target identification, disease classification, treatment response monitoring, developmental biology, immunology, neuroscience, and metabolic disease research.

Scope of the Report
Years Considered for the Study	2026-2031
Base Year	2025
Forecast Period	2026-2031
Units Considered	Value (USD billion)
Segments	Offering, Product, Service, Technology, Method, Application, End User (Product), and End User (Service)
Regions covered	North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa

The growing use of liquid biopsy-based methylation biomarkers, single-cell epigenomics, multi-omics integration, and AI-enabled data interpretation is further strengthening adoption across pharmaceutical, biotechnology, academic, clinical, and CRO settings. In addition, demand for standardized kits, high-quality antibodies, sequencing reagents, enzymes, automated sample preparation solutions, and bioinformatics platforms is improving workflow reproducibility and data reliability. However, market growth continues to be challenged by high sequencing and analysis costs, complex data interpretation, variability in antibody performance, and difficulties in standardizing epigenetic workflows for broader clinical use.

"DNA methylation segment is expected to grow at the highest CAGR during the forecast period"

The DNA methylation segment is projected to grow at the highest CAGR in the epigenetics market due to its increasing use in cancer detection, biomarker discovery, disease classification, and treatment response monitoring. DNA methylation assays are widely used to study promoter methylation, gene silencing, epigenetic aging, tumor profiling, and liquid biopsy-based diagnostics. The growing adoption of bisulfite sequencing, methylation-specific PCR, methylation arrays, and NGS-based methylation profiling is strengthening demand across pharmaceutical research, clinical laboratories, and translational studies.

"Next-generation sequencing segment holds the largest share of the market"

The next-generation sequencing segment accounts for the largest share of the epigenetics market, driven by its ability to generate high-throughput, genome-wide insights into epigenetic regulation. NGS is widely used in DNA methylation profiling, ChIP-seq, ATAC-seq, chromatin accessibility studies, and single-cell epigenomics. Its strong adoption across oncology research, biomarker discovery, drug development, and precision medicine supports its leading position. The increasing need for deeper epigenomic coverage, scalable analysis, and integration with multi-omics workflows continues to strengthen demand for NGS-based epigenetics solutions.

"The US is expected to grow at the highest CAGR during the forecast period"

The US is expected to grow at the highest CAGR in the epigenetics market due to its strong presence of sequencing, molecular biology, diagnostics, and bioinformatics companies, advanced research infrastructure, and high adoption of epigenomic technologies across research and clinical settings. Rising use of epigenetics in oncology, precision medicine, drug discovery, liquid biopsy development, and biomarker validation is driving market growth. Technologies such as next-generation sequencing, PCR & qPCR, methylation arrays, ChIP-seq, ATAC-seq, and single-cell epigenomics are widely used across pharmaceutical companies, biotechnology firms, academic institutes, CROs, and clinical laboratories.

The primary interviews conducted for this report can be categorized as follows:

By Respondent: Supply Side - 70% and Demand Side- 30%
By Designation: Managers - 45%, CXOs and Directors - 30%, and Executives - 25%
By Region: North America - 40%, Europe - 25%, Asia Pacific - 25%, Latin America - 5%, the Middle East & Africa - 5%

Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Illumina, Inc. (US), PacBio (US), Danaher Corporation (US), Bio-Rad Laboratories, Inc. (US), Active Motif, Inc. (US), New England Biolabs (US), QIAGEN (Netherlands), Zymo Research Corporation (US), Revvity (US), Hologic Diagenode (US), F. Hoffmann-La Roche Ltd. (Switzerland), Promega Corporation (US), EpigenTek Group Inc. (US), EpiCypher (US), Fios Genomics (UK), GenomeScan (Netherlands), Creative Biogene (US), BPS Bioscience, Inc. (US), Abnova Corporation (Taiwan), Creative Diagnostics (US), Biomodal (UK), 10x Genomics (US), and Novogene Co., Ltd. (China) are some of the key companies offering epigenetics products and services.

Research Coverage

This research report categorizes the epigenetics market by offering (products and services), product [kits & reagents {antibodies, isolation/extraction kits & reagents, ChIP-sequencing kits & reagents, bisulfite conversion kits & reagents, whole-genome amplification kits & reagents, CUT&RUN/CUT&TAG kits & reagents, 5-hmC & 5-mC analysis kits & reagents, histones, and other kits & reagents}, enzymes {DNA polymerases, DNA ligases, Tn5 transposase, conversion enzymes [TET & APOBEC], protein-modifying enzymes, and other enzymes}, and instruments & accessories], service (DNA methylation profiling services, chromatin profiling services, chromatin accessibility profiling services, single-cell epigenomics services, multi-omics services, and other services), technology (next-generation sequencing, PCR & qPCR, mass spectrometry, sonication, and other technologies), method (DNA methylation, histone modifications, and other methods), application (oncology, metabolic diseases, immunology, developmental biology, cardiovascular diseases, population screening, and other applications), products market by end user (academic & research institutes, pharmaceutical & biotechnology companies, hospitals & clinics, and contract research organizations), services market by end user (pharmaceutical & biotechnology companies, academic & research institutes, hospitals & clinics, and contract research organizations), and region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa).

The report's scope encompasses detailed information about the primary factors, including drivers, restraints, challenges, and opportunities, that influence the growth of the epigenetics market. A comprehensive analysis of key industry players has been performed to provide insights into their business overview, product portfolio, key strategies, new product launches, acquisitions, and recent developments related to the epigenetics market. This report also includes a competitive analysis of emerging startups in the epigenetics industry ecosystem.

Key Benefits of Buying the Report

The report will assist market leaders and new entrants by providing revenue estimates for the overall market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their businesses effectively and develop suitable go-to-market strategies. This report will enable stakeholders to grasp the market's pulse and offer information on key market drivers, restraints, opportunities, and challenges.

The report provides insights into the following pointers:

Analysis of key drivers (declining sequencing costs and time, growing emphasis on population screening programs, technological advancements in epigenetics research, rising demand for epigenetic drugs and epigenetic-based therapeutics), restraints (limited applications of epigenomic data in toxicology, data privacy concerns and security issues), opportunities (emerging applications of epigenetics, integration of multi-omics), and challenges (concerns regarding quality of antibodies, challenges associated with epigenetic editing) influencing the market growth
Product Development/Innovation: Detailed insights into newly launched products and innovations in the epigenetics market
Market Development: Comprehensive information about lucrative markets and analysis of the market across varied regions
Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the epigenetics market
Competitive Assessment: In-depth assessment of market shares, growth strategies, and products & services of leading players like Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Illumina, Inc. (US), PacBio (US), Danaher Corporation (US), Bio-Rad Laboratories, Inc. (US), Active Motif, Inc. (US), New England Biolabs (US), QIAGEN (Netherlands), Zymo Research Corporation (US), and Revvity (US), among others, for the epigenetics market

1 INTRODUCTION

1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 MARKET SCOPE
- 1.3.1 MARKET SEGMENTATION AND REGIONAL SCOPE
- 1.3.2 INCLUSIONS & EXCLUSIONS
- 1.3.3 YEARS CONSIDERED
- 1.3.4 CURRENCY CONSIDERED
1.4 STAKEHOLDERS
1.5 SUMMARY OF CHANGES

2 EXECUTIVE SUMMARY

2.1 MARKET HIGHLIGHTS AND KEY INSIGHTS
2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS
2.3 DISRUPTIVE TRENDS IN EPIGENETICS MARKET
2.4 HIGH-GROWTH SEGMENTS
2.5 REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST

3 PREMIUM INSIGHTS

3.1 EPIGENETICS MARKET OVERVIEW
3.2 NORTH AMERICA: EPIGENETICS MARKET, BY METHOD AND COUNTRY
3.3 EPIGENETICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
3.4 EPIGENETICS MARKET SHARE, BY OFFERING, 2026 VS. 2031

4 MARKET OVERVIEW

4.1 INTRODUCTION
4.2 MARKET DYNAMICS
- 4.2.1 DRIVERS
  - 4.2.1.1 Declining sequencing costs and time
  - 4.2.1.2 Growing emphasis on population-scale screening initiatives
  - 4.2.1.3 Technological advancements in epigenetics research
  - 4.2.1.4 Rising demand for epigenetic drugs and epigenetic-based therapeutics
- 4.2.2 RESTRAINTS
  - 4.2.2.1 Limited applications of epigenomic data in toxicology
  - 4.2.2.2 Data privacy concerns and security issues
- 4.2.3 OPPORTUNITIES
  - 4.2.3.1 Emerging applications of epigenetics
  - 4.2.3.2 Integration of multi-omics
- 4.2.4 CHALLENGES
  - 4.2.4.1 Concerns regarding quality of antibodies
  - 4.2.4.2 Challenges associated with epigenetic editing
4.3 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES
4.4 STRATEGIC MOVIES BY TIER-1/2/3 PLAYERS

5 INDUSTRY TRENDS

5.1 PORTER'S FIVE FORCES ANALYSIS
- 5.1.1 BARGAINING POWER OF SUPPLIERS
- 5.1.2 BARGAINING POWER OF BUYERS
- 5.1.3 THREAT OF NEW ENTRANTS
- 5.1.4 THREAT OF SUBSTITUTES
- 5.1.5 INTENSITY OF COMPETITIVE RIVALRY
5.2 MACROECONOMIC OUTLOOK
- 5.2.1 INTRODUCTION
- 5.2.2 GDP TRENDS AND FORECAST
- 5.2.3 TRENDS IN GLOBAL HEALTHCARE INDUSTRY
- 5.2.4 TRENDS IN GLOBAL BIOTECH & PHARMA INDUSTRY
5.3 VALUE CHAIN ANALYSIS
5.4 ECOSYSTEM ANALYSIS
- 5.4.1 ROLE OF PLAYERS IN ECOSYSTEM
5.5 PRICING ANALYSIS
- 5.5.1 AVERAGE SELLING PRICE TREND OF PRODUCTS, BY KEY PLAYER, 2023-2025
  - 5.5.1.1 Average selling price trend, by instrument, 2023-2025
  - 5.5.1.2 Average selling price trend, by kits & reagents, 2023-2025
- 5.5.2 AVERAGE SELLING PRICE TREND, BY REGION, 2023-2025
5.6 TRADE ANALYSIS
- 5.6.1 IMPORT SCENARIO (HS CODE 9027.50)
- 5.6.2 EXPORT SCENARIO (HS CODE 9027.50)
- 5.6.3 IMPORT SCENARIO (HS CODE 3822.00)
- 5.6.4 EXPORT SCENARIO (HS CODE 3822.00)
5.7 KEY CONFERENCES & EVENTS, 2026-2027
5.8 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
5.9 INVESTMENT & FUNDING SCENARIO
5.10 CASE STUDY ANALYSIS
- 5.10.1 CFDNA METHYLOME-FRAGMENTOME PROFILING STRENGTHENS MULTICANCER DETECTION
- 5.10.2 5-BASE NGS WORKFLOW ENABLES INTEGRATED METHYLATION AND VARIANT PROFILING
- 5.10.3 LONG-READ SEQUENCING SCALES NATIVE EPIGENOME ANALYSIS IN AGING RESEARCH
5.11 IMPACT OF 2025 US TARIFF ON EPIGENETICS MARKET
- 5.11.1 INTRODUCTION
- 5.11.2 KEY TARIFF RATES
- 5.11.3 PRICE IMPACT ANALYSIS
- 5.11.4 IMPACT ON COUNTRIES/REGIONS
  - 5.11.4.1 US
  - 5.11.4.2 Europe
  - 5.11.4.3 Asia Pacific
- 5.11.5 IMPACT ON END-USE INDUSTRIES
  - 5.11.5.1 Pharmaceutical and biotechnology companies
  - 5.11.5.2 Contract research organizations
  - 5.11.5.3 Academic and research institutes

6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS

6.1 INTRODUCTION
- 6.1.1 KEY TECHNOLOGIES
  - 6.1.1.1 DNA methylation conversion technologies
  - 6.1.1.2 Chromatin immunoprecipitation/ChIP
  - 6.1.1.3 ATAC-based chromatin accessibility profiling
- 6.1.2 COMPLEMENTARY TECHNOLOGIES
  - 6.1.2.1 Single-cell partitioning and epigenomic barcoding
  - 6.1.2.2 AI/ML-based epigenomic interpretation
- 6.1.3 ADJACENT TECHNOLOGIES
  - 6.1.3.1 CRISPR-based epigenome modulation
  - 6.1.3.2 Spatial epigenomics
6.2 TECHNOLOGY ROADMAP
6.3 PATENT ANALYSIS
- 6.3.1 METHODOLOGY
- 6.3.2 NUMBER OF PATENTS FILED, BY DOCUMENT TYPE
- 6.3.3 LIST OF KEY PATENTS
6.4 FUTURE APPLICATIONS
6.5 IMPACT OF AI/GEN AI ON EPIGENETICS MARKET
- 6.5.1 TOP USE CASES AND MARKET POTENTIAL
- 6.5.2 BEST PRACTICES IN AI-ENABLED EPIGENETICS WORKFLOWS
- 6.5.3 CASE STUDIES OF AI IMPLEMENTATION IN EPIGENETICS MARKET
- 6.5.4 INTERCONNECTED ECOSYSTEM AND IMPACT ON MARKET PLAYERS
- 6.5.5 CLIENTS' READINESS TO ADOPT AI-INTEGRATED EPIGENETICS TECHNOLOGIES

7 REGULATORY LANDSCAPE AND SUSTAINABILITY INITIATIVES

7.1 REGIONAL REGULATIONS AND COMPLIANCE
- 7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
- 7.1.2 INDUSTRY STANDARDS
  - 7.1.2.1 North America
  - 7.1.2.2 Europe
  - 7.1.2.3 Asia Pacific
  - 7.1.2.4 Rest of the World
7.2 SUSTAINABILITY INITIATIVES
7.3 IMPACT OF REGULATORY POLICIES ON SUSTAINABILITY INITIATIVES
7.4 CERTIFICATIONS, LABELING, & ECO-STANDARDS

8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR

8.1 DECISION-MAKING PROCESS
8.2 KEY STAKEHOLDERS INVOLVED IN BUYING PROCESS AND THEIR EVALUATION CRITERIA
- 8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS
- 8.2.2 KEY BUYING CRITERIA
8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES
8.4 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES

9 EPIGENETICS MARKET, BY OFFERING

9.1 INTRODUCTION
9.2 PRODUCTS
- 9.2.1 RISING ADOPTION OF WORKFLOW-READY EPIGENETICS PRODUCTS TO PROPEL MARKET
9.3 SERVICES
- 9.3.1 RISING OUTSOURCING OF COMPLEX EPIGENOMIC WORKFLOWS TO DRIVE MARKET

10 EPIGENETICS MARKET, BY PRODUCT

10.1 INTRODUCTION
10.2 KITS & REAGENTS
- 10.2.1 ANTIBODIES
  - 10.2.1.1 Growing demand for recombinant antibodies for detection of epigenetic targets to propel market
- 10.2.2 ISOLATION/EXTRACTION KITS & REAGENTS
  - 10.2.2.1 Rising need for high-quality, automation-ready sample preparation to propel market
- 10.2.3 CHIP-SEQUENCING KITS & REAGENTS
  - 10.2.3.1 Versatile applications of chromatin immunoprecipitation pertaining to epigenetic regulatory systems to boost market
- 10.2.4 BISULFITE CONVERSION KITS & REAGENTS
  - 10.2.4.1 Effective outcomes associated with bisulfite conversion to sustain growth
- 10.2.5 WHOLE-GENOME AMPLIFICATION KITS & REAGENTS
  - 10.2.5.1 Rising use of low-input and single-cell epigenomic workflows to stimulate growth
- 10.2.6 CUT&RUN/CUT&TAG KITS & REAGENTS
  - 10.2.6.1 Rising adoption of low-input chromatin profiling workflows to stimulate growth
- 10.2.7 5-HMC & 5-MC ANALYSIS KITS & REAGENTS
  - 10.2.7.1 Introduction of unique kits for 5-mC and 5-hmC analysis to support growth
- 10.2.8 HISTONES
  - 10.2.8.1 Rising importance of chromatin-associated proteins and histones in epigenetic research to propel growth
- 10.2.9 OTHER KITS & REAGENTS
10.3 ENZYMES
- 10.3.1 DNA POLYMERASES
  - 10.3.1.1 Rising need for uracil-tolerant, low-bias DNA amplification to facilitate growth
- 10.3.2 DNA LIGASES
  - 10.3.2.1 Rising need for efficient adapter ligation in low-input epigenomic library preparation to spur growth
- 10.3.3 TN5 TRANSPOSASE
  - 10.3.3.1 Rising adoption of tagmentation-based chromatin profiling to facilitate growth
- 10.3.4 CONVERSION ENZYMES
  - 10.3.4.1 Rising shift toward enzymatic DNA conversion for low-damage methylome profiling to spur growth
- 10.3.5 PROTEIN-MODIFYING ENZYMES
  - 10.3.5.1 Rising focus on histone post-translational modification analysis to spur growth
- 10.3.6 OTHER ENZYMES
10.4 INSTRUMENTS & ACCESSORIES
- 10.4.1 RISING ADOPTION OF HIGH-THROUGHPUT, AUTOMATED, AND LONG-READ EPIGENOMIC PLATFORMS TO EXPEDITE GROWTH

11 EPIGENETICS MARKET, BY SERVICE

11.1 INTRODUCTION
11.2 DNA METHYLATION PROFILING SERVICES
- 11.2.1 OUTSOURCING OF COMPLEX METHYLATION WORKFLOWS AND ONCOLOGY BIOMARKER RESEARCH TO DRIVE MARKET
11.3 CHROMATIN PROFILING SERVICES
- 11.3.1 RISING OUTSOURCING OF LOW-INPUT AND MULTI-OMIC CHROMATIN MAPPING WORKFLOWS TO DRIVE MARKET
11.4 CHROMATIN ACCESSIBILITY PROFILING SERVICES
- 11.4.1 RISING USE OF SINGLE-CELL EPIGENOMIC PROFILING IN EMBRYO AND LINEAGE-DEVELOPMENT RESEARCH TO PROPEL MARKET
11.5 SINGLE-CELL EPIGENOMICS SERVICES
- 11.5.1 RISING NEED FOR CELL-LEVEL REGULATORY INSIGHTS TO AID GROWTH
11.6 MULTI-OMICS SERVICES
- 11.6.1 RISING DEMAND FOR INTEGRATED EPIGENOMIC, GENOMIC, AND TRANSCRIPTOMIC INTERPRETATION TO SUPPORT GROWTH
11.7 OTHER SERVICES

12 EPIGENETICS MARKET, BY TECHNOLOGY

12.1 INTRODUCTION
12.2 NEXT-GENERATION SEQUENCING
- 12.2.1 INCREASING LAUNCHES OF NGS PLATFORMS TO DRIVE GROWTH
12.3 PCR & QPCR
- 12.3.1 RISING NUMBER OF PCR-BASED EPIGENETICS SERVICE PROVIDERS TO DRIVE MARKET
12.4 MASS SPECTROMETRY
- 12.4.1 GROWING DEMAND FOR MASS SPECTROMETRY IN COMPREHENSIVE STUDIES ON HISTONE EPIGENETICS TO BOOST MARKET
12.5 SONICATION
- 12.5.1 RISING USE OF SONICATION IN SCIENTIFIC AND INDUSTRIAL SETTINGS TO DRIVE MARKET
12.6 OTHER TECHNOLOGIES

13 EPIGENETICS MARKET, BY METHOD

13.1 INTRODUCTION
13.2 DNA METHYLATION
- 13.2.1 RISING USE OF METHYLATION-BASED BIOMARKERS IN ONCOLOGY, LIQUID BIOPSY, AND PRECISION MEDICINE TO SPUR GROWTH
13.3 HISTONE MODIFICATION
- 13.3.1 EXPANDING USE OF HISTONE MODIFICATION PROFILING IN CHROMATIN BIOLOGY, DRUG DISCOVERY, AND MULTI-OMICS RESEARCH TO DRIVE MARKET
13.4 OTHER METHODS

14 EPIGENETICS MARKET, BY APPLICATION

14.1 INTRODUCTION
14.2 ONCOLOGY
- 14.2.1 RISING USE OF EPIGENETIC BIOMARKERS AND CHROMATIN-REGULATING DRUG TARGETS TO BOOST MARKET
14.3 METABOLIC DISEASES
- 14.3.1 INCREASING USE OF DNA METHYLATION BIOMARKERS TO ADVANCE METABOLIC DISEASE RISK PREDICTION AND THERAPEUTIC RESEARCH
14.4 IMMUNOLOGY
- 14.4.1 RISING USE OF EPIGENETIC IMMUNE PROFILING TO DRIVE MARKET
14.5 DEVELOPMENTAL BIOLOGY
- 14.5.1 INCREASED USE OF SINGLE-CELL EPIGENOMIC PROFILING IN EMBRYO AND LINEAGE-DEVELOPMENT RESEARCH TO PROPEL MARKET
14.6 CARDIOVASCULAR DISEASES
- 14.6.1 RISING USE OF DNA METHYLATION BIOMARKERS FOR CARDIOVASCULAR RISK PREDICTION AND THERAPEUTIC TARGET DISCOVERY TO AID GROWTH
14.7 POPULATION SCREENING
- 14.7.1 INCREASING USE OF DNA METHYLATION BIOMARKERS FOR EXPOSURE-LINKED POPULATION RISK ASSESSMENT TO AID GROWTH
14.8 OTHER APPLICATIONS

15 EPIGENETIC PRODUCTS MARKET, BY END USER

15.1 INTRODUCTION
15.2 ACADEMIC & RESEARCH INSTITUTES
- 15.2.1 INCREASED IN-HOUSE ADOPTION OF ADVANCED EPIGENOMICS PRODUCTS ACROSS ACADEMIC DISCOVERY RESEARCH TO FAVOR GROWTH
15.3 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
- 15.3.1 RISING USE OF EPIGENETICS PRODUCTS IN DRUG DISCOVERY TO PROPEL MARKET
15.4 HOSPITALS & CLINICS
- 15.4.1 RISING INTEGRATION OF METHYLATION-BASED MOLECULAR PROFILING IN HOSPITAL ONCOLOGY WORKFLOWS TO PROPEL MARKET
15.5 CONTRACT RESEARCH ORGANIZATIONS
- 15.5.1 INCREASING DEMAND FOR STANDARDIZED AND SCALABLE EPIGENOMIC WORKFLOWS TO DRIVE MARKET

16 EPIGENETICS SERVICES MARKET, BY END USER

16.1 INTRODUCTION
16.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
- 16.2.1 RISING USE OF OUTSOURCED EPIGENETIC BIOMARKER AND TARGET-VALIDATION SERVICES TO ACCELERATE DRUG DEVELOPMENT DECISIONS
16.3 ACADEMIC & RESEARCH INSTITUTES
- 16.3.1 INCREASING VOLUME OF HIGH-THROUGHPUT EPIGENOMIC DATA TO AUGMENT GROWTH
16.4 HOSPITALS & CLINICS
- 16.4.1 RISING USE OF OUTSOURCED METHYLATION PROFILING AND CLASSIFIER-BASED INTERPRETATION TO AID GROWTH

17 EPIGENETICS MARKET, BY REGION

17.1 INTRODUCTION
17.2 NORTH AMERICA
- 17.2.1 US
  - 17.2.1.1 Strong pharmaceutical R&D intensity and advanced genomics infrastructure to drive market
- 17.2.2 CANADA
  - 17.2.2.1 Presence of advanced clinical genomics infrastructure to support market growth
17.3 EUROPE
- 17.3.1 GERMANY
  - 17.3.1.1 Established life sciences supply ecosystem to drive market
- 17.3.2 UK
  - 17.3.2.1 Growing emphasis on precision medicine to propel market
- 17.3.3 FRANCE
  - 17.3.3.1 Strong oncology research ecosystem to support market growth
- 17.3.4 ITALY
  - 17.3.4.1 High incidence of cancer to drive market
- 17.3.5 SPAIN
  - 17.3.5.1 Well-established network of research centers and universities to propel market
- 17.3.6 REST OF EUROPE
17.4 ASIA PACIFIC
- 17.4.1 CHINA
  - 17.4.1.1 Advanced methylation detection and sequencing service capacity to accelerate growth
- 17.4.2 JAPAN
  - 17.4.2.1 Increasing collaborations between research & academic organizations to favor growth
- 17.4.3 INDIA
  - 17.4.3.1 Expanding genomics infrastructure to drive market
- 17.4.4 AUSTRALIA
  - 17.4.4.1 Strong genomics infrastructure to propel market
- 17.4.5 SOUTH KOREA
  - 17.4.5.1 Methylation profiling and AI-enabled epigenomic analysis to foster growth
- 17.4.6 REST OF ASIA PACIFIC
17.5 LATIN AMERICA
- 17.5.1 BRAZIL
  - 17.5.1.1 Rising prevalence of chronic diseases to drive market
- 17.5.2 MEXICO
  - 17.5.2.1 Growing adoption of cutting-edge technologies to drive market
- 17.5.3 REST OF LATIN AMERICA
17.6 MIDDLE EAST
- 17.6.1 GCC COUNTRIES
  - 17.6.1.1 Saudi Arabia
    - 17.6.1.1.1 Growing healthcare expenditure to propel market
  - 17.6.1.2 UAE
    - 17.6.1.2.1 National genomics programs and methylation-enabled sequencing to spur growth
  - 17.6.1.3 Rest of GCC countries
- 17.6.2 REST OF MIDDLE EAST
17.7 AFRICA
- 17.7.1 POPULATION-SPECIFIC BIOMARKER DISCOVERY AND DISEASE-FOCUSED METHYLATION RESEARCH TO AUGMENT GROWTH

18 COMPETITIVE LANDSCAPE

18.1 INTRODUCTION
18.2 KEY PLAYER STRATEGIES/RIGHT TO WIN, JANUARY 2023-MAY 2026
18.3 REVENUE ANALYSIS
18.4 MARKET SHARE ANALYSIS, 2025
18.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025
- 18.5.1 STARS
- 18.5.2 EMERGING LEADERS
- 18.5.3 PERVASIVE PLAYERS
- 18.5.4 PARTICIPANTS
- 18.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025
  - 18.5.5.1 Company footprint
  - 18.5.5.2 Region footprint
  - 18.5.5.3 Product footprint
  - 18.5.5.4 Service footprint
  - 18.5.5.5 Method footprint
18.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
- 18.6.1 PROGRESSIVE COMPANIES
- 18.6.2 RESPONSIVE COMPANIES
- 18.6.3 DYNAMIC COMPANIES
- 18.6.4 STARTING BLOCKS
- 18.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025
  - 18.6.5.1 Detailed list of key startups/SMEs
  - 18.6.5.2 Competitive benchmarking of key startups/SMEs
18.7 COMPANY VALUATION AND FINANCIAL METRICS
- 18.7.1 COMPANY VALUATION
- 18.7.2 FINANCIAL METRICS
18.8 BRAND COMPARISON
18.9 COMPETITIVE SCENARIO
- 18.9.1 PRODUCT/SERVICE LAUNCHES
- 18.9.2 DEALS

19 COMPANY PROFILES

19.1 KEY PLAYERS
- 19.1.1 THERMO FISHER SCIENTIFIC INC.
  - 19.1.1.1 Business overview
  - 19.1.1.2 Products/services offered
  - 19.1.1.3 Recent developments
    - 19.1.1.3.1 Product launches
    - 19.1.1.3.2 Deals
  - 19.1.1.4 MnM view
    - 19.1.1.4.1 Key strengths
    - 19.1.1.4.2 Strategic choices
    - 19.1.1.4.3 Weaknesses and competitive threats
- 19.1.2 ILLUMINA, INC.
  - 19.1.2.1 Business overview
  - 19.1.2.2 Products/Services offered
  - 19.1.2.3 Recent developments
    - 19.1.2.3.1 Product launches
    - 19.1.2.3.2 Deals
  - 19.1.2.4 MnM view
    - 19.1.2.4.1 Key strengths
    - 19.1.2.4.2 Strategic choices
    - 19.1.2.4.3 Weaknesses and competitive threats
- 19.1.3 MERCK KGAA
  - 19.1.3.1 Business overview
  - 19.1.3.2 Products/Services offered
  - 19.1.3.3 MnM view
    - 19.1.3.3.1 Key strengths
    - 19.1.3.3.2 Strategic choices
    - 19.1.3.3.3 Weaknesses and competitive threats
- 19.1.4 DANAHER CORPORATION
  - 19.1.4.1 Business overview
  - 19.1.4.2 Products/Services offered
  - 19.1.4.3 Recent developments
    - 19.1.4.3.1 Deals
  - 19.1.4.4 MnM view
    - 19.1.4.4.1 Key strengths
    - 19.1.4.4.2 Strategic choices
    - 19.1.4.4.3 Weaknesses and competitive threats
- 19.1.5 BIO-RAD LABORATORIES, INC.
  - 19.1.5.1 Business overview
  - 19.1.5.2 Products/Services offered
  - 19.1.5.3 MnM view
    - 19.1.5.3.1 Key strengths
    - 19.1.5.3.2 Strategic choices
    - 19.1.5.3.3 Weaknesses and competitive threats
- 19.1.6 REVVITY
  - 19.1.6.1 Business overview
  - 19.1.6.2 Products/Services offered
- 19.1.7 PACBIO
  - 19.1.7.1 Business overview
  - 19.1.7.2 Products/Services offered
  - 19.1.7.3 Recent developments
    - 19.1.7.3.1 Product launches
    - 19.1.7.3.2 Deals
- 19.1.8 ACTIVE MOTIF, INC.
  - 19.1.8.1 Business overview
  - 19.1.8.2 Products/Services offered
  - 19.1.8.3 Recent developments
    - 19.1.8.3.1 Deals
- 19.1.9 NEW ENGLAND BIOLABS
  - 19.1.9.1 Business overview
  - 19.1.9.2 Products/Services offered
  - 19.1.9.3 Recent developments
    - 19.1.9.3.1 Product launches
    - 19.1.9.3.2 Deals
- 19.1.10 QIAGEN
  - 19.1.10.1 Business overview
  - 19.1.10.2 Products/services offered
  - 19.1.10.3 Recent developments
    - 19.1.10.3.1 Product launches
- 19.1.11 ZYMO RESEARCH CORPORATION
  - 19.1.11.1 Business overview
  - 19.1.11.2 Products/Services offered
  - 19.1.11.3 Recent developments
    - 19.1.11.3.1 Product launches
    - 19.1.11.3.2 Deals
- 19.1.12 HOLOGIC DIAGENODE
  - 19.1.12.1 Business overview
  - 19.1.12.2 Products/services offered
- 19.1.13 F. HOFFMANN-LA ROCHE LTD.
  - 19.1.13.1 Business overview
  - 19.1.13.2 Products/services offered
- 19.1.14 PROMEGA CORPORATION
  - 19.1.14.1 Business overview
  - 19.1.14.2 Products/services offered
- 19.1.15 EPIGENTEK GROUP INC.
  - 19.1.15.1 Business overview
  - 19.1.15.2 Products/Services offered
  - 19.1.15.3 Recent developments
    - 19.1.15.3.1 Product launches
19.2 OTHER PLAYERS
- 19.2.1 EPICYPHER
- 19.2.2 FIOS GENOMICS
- 19.2.3 GENOMESCAN
- 19.2.4 CREATIVE BIOGENE
- 19.2.5 BPS BIOSCIENCE, INC.
- 19.2.6 ABNOVA CORPORATION
- 19.2.7 CREATIVE DIAGNOSTICS
- 19.2.8 BIOMODAL
- 19.2.9 10X GENOMICS
- 19.2.10 NOVOGENE CO., LTD.

20 RESEARCH METHODOLOGY

20.1 RESEARCH DATA
- 20.1.1 SECONDARY DATA
  - 20.1.1.1 Key data from secondary sources
- 20.1.2 PRIMARY DATA
  - 20.1.2.1 Key data from primary sources
  - 20.1.2.2 Key primary participants
  - 20.1.2.3 Breakdown of primary interviews
  - 20.1.2.4 Key industry insights
20.2 MARKET SIZE ESTIMATION
- 20.2.1 GLOBAL EPIGENETICS MARKET ESTIMATION, 2025
- 20.2.2 SEGMENTAL MARKET SIZE ESTIMATION
20.3 MARKET GROWTH RATE PROJECTIONS
20.4 DATA TRIANGULATION
20.5 FACTOR ANALYSIS
20.6 RESEARCH ASSUMPTIONS
20.7 RESEARCH LIMITATIONS AND RISK ASSESSMENT

21 APPENDIX

21.1 DISCUSSION GUIDE
21.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
21.3 CUSTOMIZATION OPTIONS
21.4 RELATED REPORTS
21.5 AUTHOR DETAILS

簡介目錄圖表

List of Tables

TABLE 1 EPIGENETICS MARKET: INCLUSIONS AND EXCLUSIONS
TABLE 2 EPIGENETICS MARKET: IMPACT ANALYSIS OF MARKET DYNAMICS
TABLE 3 EPIGENETICS MARKET: PORTER'S FIVE FORCES ANALYSIS
TABLE 4 EPIGENETICS MARKET: ROLE OF PLAYERS IN ECOSYSTEM
TABLE 5 AVERAGE SELLING PRICE TREND OF EPIGENETIC INSTRUMENTS, 2023-2025
TABLE 6 AVERAGE SELLING PRICE TREND OF EPIGENETIC KITS & REAGENTS, 2023-2025 (USD)
TABLE 7 AVERAGE SELLING PRICE TREND OF EPIGENETIC INSTRUMENTS, BY REGION, 2023-2025 (USD)
TABLE 8 AVERAGE SELLING PRICE TREND OF EPIGENETIC KITS & REAGENTS, BY REGION, 2023-2025 (USD)
TABLE 9 IMPORT DATA FOR HS CODE 9027.50-COMPLIANT PRODUCTS, BY COUNTRY, 2021-2025 (USD THOUSAND)
TABLE 10 EXPORT DATA FOR HS CODE 9027.50-COMPLIANT PRODUCTS, BY COUNTRY, 2021-2025 (USD THOUSAND)
TABLE 11 IMPORT DATA FOR HS CODE 3822.00-COMPLIANT PRODUCTS, BY COUNTRY, 2021-2025 (USD THOUSAND)
TABLE 12 EXPORT DATA FOR HS CODE 3822.00-COMPLIANT PRODUCTS, BY COUNTRY, 2021-2025 (USD THOUSAND)
TABLE 13 EPIGENETICS MARKET: LIST OF KEY CONFERENCES & EVENTS, JANUARY 2026-JUNE 2027
TABLE 14 RECIPROCAL TARIFF RATES ADJUSTED BY US
TABLE 15 CRITICAL COMPONENTS LIKELY EXPOSED TO TARIFF CHANGES
TABLE 16 NUMBER OF PATENTS FILED, BY DOCUMENT TYPE, 2015-2025
TABLE 17 LIST OF KEY PATENTS IN EPIGENETICS MARKET, 2023-2025
TABLE 18 CASE STUDIES OF AI IMPLEMENTATION IN EPIGENETICS MARKET
TABLE 19 CLIENTS' READINESS TO ADOPT AI-INTEGRATED EPIGENETICS TECHNOLOGIES
TABLE 20 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 21 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 22 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 23 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 24 MIDDLE EAST: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 25 AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 26 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT & SERVICE
TABLE 27 KEY BUYING CRITERIA, BY END USER
TABLE 28 EPIGENETICS MARKET, BY OFFERING, 2024-2031 (USD MILLION)
TABLE 29 EPIGENETIC PRODUCTS MARKET, BY REGION, 2024-2031 (USD MILLION)
TABLE 30 NORTH AMERICA: EPIGENETIC PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 31 EUROPE: EPIGENETIC PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 32 ASIA PACIFIC: EPIGENETIC PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 33 LATIN AMERICA: EPIGENETIC PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 34 MIDDLE EAST: EPIGENETIC PRODUCTS MARKET, BY REGION, 2024-2031 (USD MILLION)
TABLE 35 GCC COUNTRIES: EPIGENETIC PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 36 EPIGENETIC SERVICES MARKET, BY REGION, 2024-2031 (USD MILLION)
TABLE 37 NORTH AMERICA: EPIGENETIC SERVICES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 38 EUROPE: EPIGENETIC SERVICES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 39 ASIA PACIFIC: EPIGENETIC SERVICES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 40 LATIN AMERICA: EPIGENETIC SERVICES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 41 MIDDLE EAST: EPIGENETIC SERVICES MARKET, BY REGION, 2024-2031 (USD MILLION)
TABLE 42 GCC COUNTRIES: EPIGENETIC SERVICES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 43 EPIGENETICS MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
TABLE 44 EPIGENETICS MARKET FOR KITS & REAGENTS, BY TYPE, 2024-2031 (USD MILLION)
TABLE 45 EPIGENETICS MARKET FOR KITS & REAGENTS, BY REGION, 2024-2031 (USD MILLION)
TABLE 46 NORTH AMERICA: EPIGENETICS MARKET FOR KITS & REAGENTS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 47 EUROPE: EPIGENETICS MARKET FOR KITS & REAGENTS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 48 ASIA PACIFIC: EPIGENETICS MARKET FOR KITS & REAGENTS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 49 LATIN AMERICA: EPIGENETICS MARKET FOR KITS & REAGENTS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 50 MIDDLE EAST: EPIGENETICS MARKET FOR KITS & REAGENTS, BY REGION, 2024-2031 (USD MILLION)
TABLE 51 GCC COUNTRIES: EPIGENETICS MARKET FOR KITS & REAGENTS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 52 EPIGENETICS MARKET FOR ANTIBODIES, BY REGION, 2024-2031 (USD MILLION)
TABLE 53 NORTH AMERICA: EPIGENETICS MARKET FOR ANTIBODIES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 54 EUROPE: EPIGENETICS MARKET FOR ANTIBODIES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 55 ASIA PACIFIC: EPIGENETICS MARKET FOR ANTIBODIES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 56 LATIN AMERICA: EPIGENETICS MARKET FOR ANTIBODIES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 57 MIDDLE EAST: EPIGENETICS MARKET FOR ANTIBODIES, BY REGION, 2024-2031 (USD MILLION)
TABLE 58 GCC COUNTRIES: EPIGENETICS MARKET FOR ANTIBODIES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 59 EPIGENETICS MARKET FOR ISOLATION/EXTRACTION KITS & REAGENTS, BY REGION, 2024-2031 (USD MILLION)
TABLE 60 NORTH AMERICA: EPIGENETICS MARKET FOR ISOLATION/EXTRACTION KITS & REAGENTS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 61 EUROPE: EPIGENETICS MARKET FOR ISOLATION/EXTRACTION KITS & REAGENTS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 62 ASIA PACIFIC: EPIGENETICS MARKET FOR ISOLATION/EXTRACTION KITS & REAGENTS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 63 LATIN AMERICA: EPIGENETICS MARKET FOR ISOLATION/EXTRACTION KITS & REAGENTS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 64 MIDDLE EAST: EPIGENETICS MARKET FOR ISOLATION/EXTRACTION KITS & REAGENTS, BY REGION, 2024-2031 (USD MILLION)
TABLE 65 GCC COUNTRIES: EPIGENETICS MARKET FOR ISOLATION/EXTRACTION KITS & REAGENTS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 66 EPIGENETICS MARKET FOR CHIP-SEQUENCING KITS & REAGENTS, BY REGION, 2024-2031 (USD MILLION)
TABLE 67 NORTH AMERICA: EPIGENETICS MARKET FOR CHIP-SEQUENCING KITS & REAGENTS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 68 EUROPE: EPIGENETICS MARKET FOR CHIP-SEQUENCING KITS & REAGENTS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 69 ASIA PACIFIC: EPIGENETICS MARKET FOR CHIP-SEQUENCING KITS & REAGENTS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 70 LATIN AMERICA: EPIGENETICS MARKET FOR CHIP-SEQUENCING KITS & REAGENTS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 71 MIDDLE EAST: EPIGENETICS MARKET FOR CHIP-SEQUENCING KITS & REAGENTS, BY REGION, 2024-2031 (USD MILLION)
TABLE 72 GCC COUNTRIES: EPIGENETICS MARKET FOR CHIP-SEQUENCING KITS & REAGENTS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 73 EPIGENETICS MARKET FOR BISULFITE CONVERSION KITS & REAGENTS, BY REGION, 2024-2031 (USD MILLION)
TABLE 74 NORTH AMERICA: EPIGENETICS MARKET FOR BISULFITE CONVERSION KITS & REAGENTS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 75 EUROPE: EPIGENETICS MARKET FOR BISULFITE CONVERSION KITS & REAGENTS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 76 ASIA PACIFIC: EPIGENETICS MARKET FOR BISULFITE CONVERSION KITS & REAGENTS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 77 LATIN AMERICA: EPIGENETICS MARKET FOR BISULFITE CONVERSION KITS & REAGENTS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 78 MIDDLE EAST: EPIGENETICS MARKET FOR BISULFITE CONVERSION KITS & REAGENTS, BY REGION, 2024-2031 (USD MILLION)
TABLE 79 GCC COUNTRIES: EPIGENETICS MARKET FOR BISULFITE CONVERSION KITS & REAGENTS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 80 EPIGENETICS MARKET FOR WHOLE-GENOME AMPLIFICATION KITS & REAGENTS, BY REGION, 2024-2031 (USD MILLION)
TABLE 81 NORTH AMERICA: EPIGENETICS MARKET FOR WHOLE-GENOME AMPLIFICATION KITS & REAGENTS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 82 EUROPE: EPIGENETICS MARKET FOR WHOLE-GENOME AMPLIFICATION KITS & REAGENTS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 83 ASIA PACIFIC: EPIGENETICS MARKET FOR WHOLE-GENOME AMPLIFICATION KITS & REAGENTS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 84 LATIN AMERICA: EPIGENETICS MARKET FOR WHOLE-GENOME AMPLIFICATION KITS & REAGENTS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 85 MIDDLE EAST: EPIGENETICS MARKET FOR WHOLE-GENOME AMPLIFICATION KITS & REAGENTS, BY REGION, 2024-2031 (USD MILLION)
TABLE 86 GCC COUNTRIES: EPIGENETICS MARKET FOR WHOLE-GENOME AMPLIFICATION KITS & REAGENTS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 87 EPIGENETICS MARKET FOR CUT&RUN/CUT&TAG KITS & REAGENTS, BY REGION, 2024-2031 (USD MILLION)
TABLE 88 NORTH AMERICA: EPIGENETICS MARKET FOR CUT&RUN/CUT&TAG KITS & REAGENTS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 89 EUROPE: EPIGENETICS MARKET FOR CUT&RUN/CUT&TAG KITS & REAGENTS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 90 ASIA PACIFIC: EPIGENETICS MARKET FOR CUT&RUN/CUT&TAG KITS & REAGENTS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 91 LATIN AMERICA: EPIGENETICS MARKET FOR CUT&RUN/CUT&TAG KITS & REAGENTS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 92 MIDDLE EAST: EPIGENETICS MARKET FOR CUT&RUN/CUT&TAG KITS & REAGENTS, BY REGION, 2024-2031 (USD MILLION)
TABLE 93 GCC COUNTRIES: EPIGENETICS MARKET FOR CUT&RUN/CUT&TAG KITS & REAGENTS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 94 EPIGENETICS MARKET FOR 5-HMC & 5-MC ANALYSIS KITS & REAGENTS, BY REGION, 2024-2031 (USD MILLION)
TABLE 95 NORTH AMERICA: EPIGENETICS MARKET FOR 5-HMC & 5-MC ANALYSIS KITS & REAGENTS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 96 EUROPE: EPIGENETICS MARKET FOR 5-HMC & 5-MC ANALYSIS KITS & REAGENTS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 97 ASIA PACIFIC: EPIGENETICS MARKET FOR 5-HMC & 5-MC ANALYSIS KITS & REAGENTS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 98 LATIN AMERICA: EPIGENETICS MARKET FOR 5-HMC & 5-MC ANALYSIS KITS & REAGENTS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 99 MIDDLE EAST: EPIGENETICS MARKET FOR 5-HMC & 5-MC ANALYSIS KITS & REAGENTS, BY REGION, 2024-2031 (USD MILLION)
TABLE 100 GCC COUNTRIES: EPIGENETICS MARKET FOR 5-HMC & 5-MC ANALYSIS KITS & REAGENTS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 101 EPIGENETICS MARKET FOR HISTONES, BY REGION, 2024-2031 (USD MILLION)
TABLE 102 NORTH AMERICA: EPIGENETICS MARKET FOR HISTONES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 103 EUROPE: EPIGENETICS MARKET FOR HISTONES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 104 ASIA PACIFIC: EPIGENETICS MARKET FOR HISTONES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 105 LATIN AMERICA: EPIGENETICS MARKET FOR HISTONES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 106 MIDDLE EAST: EPIGENETICS MARKET FOR HISTONES, BY REGION, 2024-2031 (USD MILLION)
TABLE 107 GCC COUNTRIES: EPIGENETICS MARKET FOR HISTONES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 108 EPIGENETICS MARKET FOR OTHER KITS & REAGENTS, BY REGION, 2024-2031 (USD MILLION)
TABLE 109 NORTH AMERICA: EPIGENETICS MARKET FOR OTHER KITS & REAGENTS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 110 EUROPE: EPIGENETICS MARKET FOR OTHER KITS & REAGENTS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 111 ASIA PACIFIC: EPIGENETICS MARKET FOR OTHER KITS & REAGENTS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 112 LATIN AMERICA: EPIGENETICS MARKET FOR OTHER KITS & REAGENTS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 113 MIDDLE EAST: EPIGENETICS MARKET FOR OTHER KITS & REAGENTS, BY REGION, 2024-2031 (USD MILLION)
TABLE 114 GCC COUNTRIES: EPIGENETICS MARKET FOR OTHER KITS & REAGENTS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 115 EPIGENETICS MARKET FOR ENZYMES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 116 EPIGENETICS MARKET FOR ENZYMES, BY REGION, 2024-2031 (USD MILLION)
TABLE 117 NORTH AMERICA: EPIGENETICS MARKET FOR ENZYMES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 118 EUROPE: EPIGENETICS MARKET FOR ENZYMES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 119 ASIA PACIFIC: EPIGENETICS MARKET FOR ENZYMES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 120 LATIN AMERICA: EPIGENETICS MARKET FOR ENZYMES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 121 MIDDLE EAST: EPIGENETICS MARKET FOR ENZYMES, BY REGION, 2024-2031 (USD MILLION)
TABLE 122 GCC COUNTRIES: EPIGENETICS MARKET FOR ENZYMES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 123 EPIGENETICS MARKET FOR DNA POLYMERASES, BY REGION, 2024-2031 (USD MILLION)
TABLE 124 NORTH AMERICA: EPIGENETICS MARKET FOR DNA POLYMERASES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 125 EUROPE: EPIGENETICS MARKET FOR DNA POLYMERASES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 126 ASIA PACIFIC: EPIGENETICS MARKET FOR DNA POLYMERASES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 127 LATIN AMERICA: EPIGENETICS MARKET FOR DNA POLYMERASES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 128 MIDDLE EAST: EPIGENETICS MARKET FOR DNA POLYMERASES, BY REGION, 2024-2031 (USD MILLION)
TABLE 129 GCC COUNTRIES: EPIGENETICS MARKET FOR DNA POLYMERASES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 130 EPIGENETICS MARKET FOR DNA LIGASES, BY REGION, 2024-2031 (USD MILLION)
TABLE 131 NORTH AMERICA: EPIGENETICS MARKET FOR DNA LIGASES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 132 EUROPE: EPIGENETICS MARKET FOR DNA LIGASES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 133 ASIA PACIFIC: EPIGENETICS MARKET FOR DNA LIGASES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 134 LATIN AMERICA: EPIGENETICS MARKET FOR DNA LIGASES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 135 MIDDLE EAST: EPIGENETICS MARKET FOR DNA LIGASES, BY REGION, 2024-2031 (USD MILLION)
TABLE 136 GCC COUNTRIES: EPIGENETICS MARKET FOR DNA LIGASES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 137 EPIGENETICS MARKET FOR TN5 TRANSPOSASE, BY REGION, 2024-2031 (USD MILLION)
TABLE 138 NORTH AMERICA: EPIGENETICS MARKET FOR TN5 TRANSPOSASE, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 139 EUROPE: EPIGENETICS MARKET FOR TN5 TRANSPOSASE, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 140 ASIA PACIFIC: EPIGENETICS MARKET FOR TN5 TRANSPOSASE, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 141 LATIN AMERICA: EPIGENETICS MARKET FOR TN5 TRANSPOSASE, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 142 MIDDLE EAST: EPIGENETICS MARKET FOR TN5 TRANSPOSASE, BY REGION, 2024-2031 (USD MILLION)
TABLE 143 GCC COUNTRIES: EPIGENETICS MARKET FOR TN5 TRANSPOSASE, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 144 EPIGENETICS MARKET FOR CONVERSION ENZYMES, BY REGION, 2024-2031 (USD MILLION)
TABLE 145 NORTH AMERICA: EPIGENETICS MARKET FOR CONVERSION ENZYMES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 146 EUROPE: EPIGENETICS MARKET FOR CONVERSION ENZYMES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 147 ASIA PACIFIC: EPIGENETICS MARKET FOR CONVERSION ENZYMES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 148 LATIN AMERICA: EPIGENETICS MARKET FOR CONVERSION ENZYMES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 149 MIDDLE EAST: EPIGENETICS MARKET FOR CONVERSION ENZYMES, BY REGION, 2024-2031 (USD MILLION)
TABLE 150 GCC COUNTRIES: EPIGENETICS MARKET FOR CONVERSION ENZYMES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 151 EPIGENETICS MARKET FOR PROTEIN-MODIFYING ENZYMES, BY REGION, 2024-2031 (USD MILLION)
TABLE 152 NORTH AMERICA: EPIGENETICS MARKET FOR PROTEIN-MODIFYING ENZYMES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 153 EUROPE: EPIGENETICS MARKET FOR PROTEIN-MODIFYING ENZYMES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 154 ASIA PACIFIC: EPIGENETICS MARKET FOR PROTEIN-MODIFYING ENZYMES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 155 LATIN AMERICA: EPIGENETICS MARKET FOR PROTEIN-MODIFYING ENZYMES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 156 MIDDLE EAST: EPIGENETICS MARKET FOR PROTEIN-MODIFYING ENZYMES, BY REGION, 2024-2031 (USD MILLION)
TABLE 157 GCC COUNTRIES: EPIGENETICS MARKET FOR PROTEIN-MODIFYING ENZYMES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 158 EPIGENETICS MARKET FOR OTHER ENZYMES, BY REGION, 2024-2031 (USD MILLION)
TABLE 159 NORTH AMERICA: EPIGENETICS MARKET FOR OTHER ENZYMES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 160 EUROPE: EPIGENETICS MARKET FOR OTHER ENZYMES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 161 ASIA PACIFIC: EPIGENETICS MARKET FOR OTHER ENZYMES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 162 LATIN AMERICA: EPIGENETICS MARKET FOR OTHER ENZYMES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 163 MIDDLE EAST: EPIGENETICS MARKET FOR OTHER ENZYMES, BY REGION, 2024-2031 (USD MILLION)
TABLE 164 GCC COUNTRIES: EPIGENETICS MARKET FOR OTHER ENZYMES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 165 EPIGENETICS MARKET FOR INSTRUMENTS & ACCESSORIES, BY REGION, 2024-2031 (USD MILLION)
TABLE 166 NORTH AMERICA: EPIGENETICS MARKET FOR INSTRUMENTS & ACCESSORIES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 167 EUROPE: EPIGENETICS MARKET FOR INSTRUMENTS & ACCESSORIES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 168 ASIA PACIFIC: EPIGENETICS MARKET FOR INSTRUMENTS & ACCESSORIES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 169 LATIN AMERICA: EPIGENETICS MARKET FOR INSTRUMENTS & ACCESSORIES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 170 MIDDLE EAST: EPIGENETICS MARKET FOR INSTRUMENTS & ACCESSORIES, BY REGION, 2024-2031 (USD MILLION)
TABLE 171 GCC COUNTRIES: EPIGENETICS MARKET FOR INSTRUMENTS & ACCESSORIES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 172 EPIGENETICS MARKET, BY SERVICE, 2024-2031 (USD MILLION)
TABLE 173 EPIGENETICS MARKET FOR DNA METHYLATION PROFILING SERVICES, BY REGION, 2024-2031 (USD MILLION)
TABLE 174 NORTH AMERICA: EPIGENETICS MARKET FOR DNA METHYLATION PROFILING SERVICES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 175 EUROPE: EPIGENETICS MARKET FOR DNA METHYLATION PROFILING SERVICES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 176 ASIA PACIFIC: EPIGENETICS MARKET FOR DNA METHYLATION PROFILING SERVICES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 177 LATIN AMERICA: EPIGENETICS MARKET FOR DNA METHYLATION PROFILING SERVICES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 178 MIDDLE EAST: EPIGENETICS MARKET FOR DNA METHYLATION PROFILING SERVICES, BY REGION, 2024-2031 (USD MILLION)
TABLE 179 GCC COUNTRIES: EPIGENETICS MARKET FOR DNA METHYLATION PROFILING SERVICES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 180 EPIGENETICS MARKET FOR CHROMATIN PROFILING SERVICES, BY REGION, 2024-2031 (USD MILLION)
TABLE 181 NORTH AMERICA: EPIGENETICS MARKET FOR CHROMATIN PROFILING SERVICES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 182 EUROPE: EPIGENETICS MARKET FOR CHROMATIN PROFILING SERVICES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 183 ASIA PACIFIC: EPIGENETICS MARKET FOR CHROMATIN PROFILING SERVICES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 184 LATIN AMERICA: EPIGENETICS MARKET FOR CHROMATIN PROFILING SERVICES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 185 MIDDLE EAST: EPIGENETICS MARKET FOR CHROMATIN PROFILING SERVICES, BY REGION, 2024-2031 (USD MILLION)
TABLE 186 GCC COUNTRIES: EPIGENETICS MARKET FOR CHROMATIN PROFILING SERVICES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 187 EPIGENETICS MARKET FOR CHROMATIN ACCESSIBILITY PROFILING SERVICES, BY REGION, 2024-2031 (USD MILLION)
TABLE 188 NORTH AMERICA: EPIGENETICS MARKET FOR CHROMATIN ACCESSIBILITY PROFILING SERVICES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 189 EUROPE: EPIGENETICS MARKET FOR CHROMATIN ACCESSIBILITY PROFILING SERVICES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 190 ASIA PACIFIC: EPIGENETICS MARKET FOR CHROMATIN ACCESSIBILITY PROFILING SERVICES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 191 LATIN AMERICA: EPIGENETICS MARKET FOR CHROMATIN ACCESSIBILITY PROFILING SERVICES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 192 MIDDLE EAST: EPIGENETICS MARKET FOR CHROMATIN ACCESSIBILITY PROFILING SERVICES, BY REGION, 2024-2031 (USD MILLION)
TABLE 193 GCC COUNTRIES: EPIGENETICS MARKET FOR CHROMATIN ACCESSIBILITY PROFILING SERVICES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 194 EPIGENETICS MARKET FOR SINGLE-CELL EPIGENOMICS SERVICES, BY REGION, 2024-2031 (USD MILLION)
TABLE 195 NORTH AMERICA: EPIGENETICS MARKET FOR SINGLE-CELL EPIGENOMICS SERVICES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 196 EUROPE: EPIGENETICS MARKET FOR SINGLE-CELL EPIGENOMICS SERVICES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 197 ASIA PACIFIC: EPIGENETICS MARKET FOR SINGLE-CELL EPIGENOMICS SERVICES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 198 LATIN AMERICA: EPIGENETICS MARKET FOR SINGLE-CELL EPIGENOMICS SERVICES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 199 MIDDLE EAST: EPIGENETICS MARKET FOR SINGLE-CELL EPIGENOMICS SERVICES, BY REGION, 2024-2031 (USD MILLION)
TABLE 200 GCC COUNTRIES: EPIGENETICS MARKET FOR SINGLE-CELL EPIGENOMICS SERVICES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 201 EPIGENETICS MARKET FOR MULTI-OMICS SERVICES, BY REGION, 2024-2031 (USD MILLION)
TABLE 202 NORTH AMERICA: EPIGENETICS MARKET FOR MULTI-OMICS SERVICES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 203 EUROPE: EPIGENETICS MARKET FOR MULTI-OMICS SERVICES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 204 ASIA PACIFIC: EPIGENETICS MARKET FOR MULTI-OMICS SERVICES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 205 LATIN AMERICA: EPIGENETICS MARKET FOR MULTI-OMICS SERVICES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 206 MIDDLE EAST: EPIGENETICS MARKET FOR MULTI-OMICS SERVICES, BY REGION, 2024-2031 (USD MILLION)
TABLE 207 GCC COUNTRIES: EPIGENETICS MARKET FOR MULTI-OMICS SERVICES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 208 EPIGENETICS MARKET FOR OTHER SERVICES, BY REGION, 2024-2031 (USD MILLION)
TABLE 209 NORTH AMERICA: EPIGENETICS MARKET FOR OTHER SERVICES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 210 EUROPE: EPIGENETICS MARKET FOR OTHER SERVICES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 211 ASIA PACIFIC: EPIGENETICS MARKET FOR OTHER SERVICES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 212 LATIN AMERICA: EPIGENETICS MARKET FOR OTHER SERVICES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 213 MIDDLE EAST: EPIGENETICS MARKET FOR OTHER SERVICES, BY REGION, 2024-2031 (USD MILLION)
TABLE 214 GCC COUNTRIES: EPIGENETICS MARKET FOR OTHER SERVICES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 215 EPIGENETICS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
TABLE 216 EPIGENETICS MARKET FOR NEXT-GENERATION SEQUENCING, BY REGION, 2024-2031 (USD MILLION)
TABLE 217 NORTH AMERICA: EPIGENETICS MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 218 EUROPE: EPIGENETICS MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 219 ASIA PACIFIC: EPIGENETICS MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 220 LATIN AMERICA: EPIGENETICS MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 221 MIDDLE EAST: EPIGENETICS MARKET FOR NEXT-GENERATION SEQUENCING, BY REGION, 2024-2031 (USD MILLION)
TABLE 222 GCC COUNTRIES: EPIGENETICS MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 223 EPIGENETICS MARKET FOR PCR & QPCR, BY REGION, 2024-2031 (USD MILLION)
TABLE 224 NORTH AMERICA: EPIGENETICS MARKET FOR PCR & QPCR, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 225 EUROPE: EPIGENETICS MARKET FOR PCR & QPCR, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 226 ASIA PACIFIC: EPIGENETICS MARKET FOR PCR & QPCR, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 227 LATIN AMERICA: EPIGENETICS MARKET FOR PCR & QPCR, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 228 MIDDLE EAST: EPIGENETICS MARKET FOR PCR & QPCR, BY REGION, 2024-2031 (USD MILLION)
TABLE 229 GCC COUNTRIES: EPIGENETICS MARKET FOR PCR & QPCR, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 230 EPIGENETICS MARKET FOR MASS SPECTROMETRY, BY REGION, 2024-2031 (USD MILLION)
TABLE 231 NORTH AMERICA: EPIGENETICS MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 232 EUROPE: EPIGENETICS MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 233 ASIA PACIFIC: EPIGENETICS MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 234 LATIN AMERICA: EPIGENETICS MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 235 MIDDLE EAST: EPIGENETICS MARKET FOR MASS SPECTROMETRY, BY REGION, 2024-2031 (USD MILLION)
TABLE 236 GCC COUNTRIES: EPIGENETICS MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 237 EPIGENETICS MARKET FOR SONICATION, BY REGION, 2024-2031 (USD MILLION)
TABLE 238 NORTH AMERICA: EPIGENETICS MARKET FOR SONICATION, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 239 EUROPE: EPIGENETICS MARKET FOR SONICATION, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 240 ASIA PACIFIC: EPIGENETICS MARKET FOR SONICATION, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 241 LATIN AMERICA: EPIGENETICS MARKET FOR SONICATION, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 242 MIDDLE EAST: EPIGENETICS MARKET FOR SONICATION, BY REGION, 2024-2031 (USD MILLION)
TABLE 243 GCC COUNTRIES: EPIGENETICS MARKET FOR SONICATION, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 244 EPIGENETICS MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2024-2031 (USD MILLION)
TABLE 245 NORTH AMERICA: EPIGENETICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 246 EUROPE: EPIGENETICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 247 ASIA PACIFIC: EPIGENETICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 248 LATIN AMERICA: EPIGENETICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 249 MIDDLE EAST: EPIGENETICS MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2024-2031 (USD MILLION)
TABLE 250 GCC COUNTRIES: EPIGENETICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 251 EPIGENETICS MARKET, BY METHOD, 2024-2031 (USD MILLION)
TABLE 252 EPIGENETICS MARKET FOR DNA METHYLATION, BY REGION, 2024-2031 (USD MILLION)
TABLE 253 NORTH AMERICA: EPIGENETICS MARKET FOR DNA METHYLATION, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 254 EUROPE: EPIGENETICS MARKET FOR DNA METHYLATION, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 255 ASIA PACIFIC: EPIGENETICS MARKET FOR DNA METHYLATION, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 256 LATIN AMERICA: EPIGENETICS MARKET FOR DNA METHYLATION, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 257 MIDDLE EAST: EPIGENETICS MARKET FOR DNA METHYLATION, BY REGION, 2024-2031 (USD MILLION)
TABLE 258 GCC COUNTRIES: EPIGENETICS MARKET FOR DNA METHYLATION, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 259 COMMON HISTONE MODIFICATIONS AND RESPECTIVE LOCATIONS
TABLE 260 EPIGENETICS MARKET FOR HISTONE MODIFICATION, BY REGION, 2024-2031 (USD MILLION)
TABLE 261 NORTH AMERICA: EPIGENETICS MARKET FOR HISTONE MODIFICATION, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 262 EUROPE: EPIGENETICS MARKET FOR HISTONE MODIFICATION, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 263 ASIA PACIFIC: EPIGENETICS MARKET FOR HISTONE MODIFICATION, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 264 LATIN AMERICA: EPIGENETICS MARKET FOR HISTONE MODIFICATION, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 265 MIDDLE EAST: EPIGENETICS MARKET FOR HISTONE MODIFICATION, BY REGION, 2024-2031 (USD MILLION)
TABLE 266 GCC COUNTRIES: EPIGENETICS MARKET FOR HISTONE MODIFICATION, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 267 EPIGENETICS MARKET FOR OTHER METHODS, BY REGION, 2024-2031 (USD MILLION)
TABLE 268 NORTH AMERICA: EPIGENETICS MARKET FOR OTHER METHODS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 269 EUROPE: EPIGENETICS MARKET FOR OTHER METHODS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 270 ASIA PACIFIC: EPIGENETICS MARKET FOR OTHER METHODS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 271 LATIN AMERICA: EPIGENETICS MARKET FOR OTHER METHODS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 272 MIDDLE EAST: EPIGENETICS MARKET FOR OTHER METHODS, BY REGION, 2024-2031 (USD MILLION)
TABLE 273 GCC COUNTRIES: EPIGENETICS MARKET FOR OTHER METHODS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 274 EPIGENETICS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
TABLE 275 EPIGENOME-TARGETING CANCER DRUGS APPROVED OR IN CLINICAL TRIALS
TABLE 276 EPIGENETICS MARKET FOR ONCOLOGY, BY REGION, 2024-2031 (USD MILLION)
TABLE 277 NORTH AMERICA: EPIGENETICS MARKET FOR ONCOLOGY, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 278 EUROPE: EPIGENETICS MARKET FOR ONCOLOGY, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 279 ASIA PACIFIC: EPIGENETICS MARKET FOR ONCOLOGY, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 280 LATIN AMERICA: EPIGENETICS MARKET FOR ONCOLOGY, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 281 MIDDLE EAST: EPIGENETICS MARKET FOR ONCOLOGY, BY REGION, 2024-2031 (USD MILLION)
TABLE 282 GCC COUNTRIES: EPIGENETICS MARKET FOR ONCOLOGY, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 283 EPIGENETICS MARKET FOR METABOLIC DISEASES, BY REGION, 2024-2031 (USD MILLION)
TABLE 284 NORTH AMERICA: EPIGENETICS MARKET FOR METABOLIC DISEASES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 285 EUROPE: EPIGENETICS MARKET FOR METABOLIC DISEASES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 286 ASIA PACIFIC: EPIGENETICS MARKET FOR METABOLIC DISEASES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 287 LATIN AMERICA: EPIGENETICS MARKET FOR METABOLIC DISEASES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 288 MIDDLE EAST: EPIGENETICS MARKET FOR METABOLIC DISEASES, BY REGION, 2024-2031 (USD MILLION)
TABLE 289 GCC COUNTRIES: EPIGENETICS MARKET FOR METABOLIC DISEASES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 290 EPIGENETICS MARKET FOR IMMUNOLOGY, BY REGION, 2024-2031 (USD MILLION)
TABLE 291 NORTH AMERICA: EPIGENETICS MARKET FOR IMMUNOLOGY, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 292 EUROPE: EPIGENETICS MARKET FOR IMMUNOLOGY, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 293 ASIA PACIFIC: EPIGENETICS MARKET FOR IMMUNOLOGY, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 294 LATIN AMERICA: EPIGENETICS MARKET FOR IMMUNOLOGY, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 295 MIDDLE EAST: EPIGENETICS MARKET FOR IMMUNOLOGY, BY REGION, 2024-2031 (USD MILLION)
TABLE 296 GCC COUNTRIES: EPIGENETICS MARKET FOR IMMUNOLOGY, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 297 EPIGENETICS MARKET FOR DEVELOPMENTAL BIOLOGY, BY REGION, 2024-2031 (USD MILLION)
TABLE 298 NORTH AMERICA: EPIGENETICS MARKET FOR DEVELOPMENTAL BIOLOGY, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 299 EUROPE: EPIGENETICS MARKET FOR DEVELOPMENTAL BIOLOGY, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 300 ASIA PACIFIC: EPIGENETICS MARKET FOR DEVELOPMENTAL BIOLOGY, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 301 LATIN AMERICA: EPIGENETICS MARKET FOR DEVELOPMENTAL BIOLOGY, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 302 MIDDLE EAST: EPIGENETICS MARKET FOR DEVELOPMENTAL BIOLOGY, BY REGION, 2024-2031 (USD MILLION)
TABLE 303 GCC COUNTRIES: EPIGENETICS MARKET FOR DEVELOPMENTAL BIOLOGY, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 304 EPIGENETICS MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2024-2031 (USD MILLION)
TABLE 305 NORTH AMERICA: EPIGENETICS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 306 EUROPE: EPIGENETICS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 307 ASIA PACIFIC: EPIGENETICS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 308 LATIN AMERICA: EPIGENETICS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 309 MIDDLE EAST: EPIGENETICS MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2024-2031 (USD MILLION)
TABLE 310 GCC COUNTRIES: EPIGENETICS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 311 EPIGENETICS MARKET FOR POPULATION SCREENING, BY REGION, 2024-2031 (USD MILLION)
TABLE 312 NORTH AMERICA: EPIGENETICS MARKET FOR POPULATION SCREENING, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 313 EUROPE: EPIGENETICS MARKET FOR POPULATION SCREENING, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 314 ASIA PACIFIC: EPIGENETICS MARKET FOR POPULATION SCREENING, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 315 LATIN AMERICA: EPIGENETICS MARKET FOR POPULATION SCREENING, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 316 MIDDLE EAST: EPIGENETICS MARKET FOR POPULATION SCREENING, BY REGION, 2024-2031 (USD MILLION)
TABLE 317 GCC COUNTRIES: EPIGENETICS MARKET FOR POPULATION SCREENING, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 318 EPIGENETICS MARKET FOR OTHER APPLICATIONS, BY REGION, 2024-2031 (USD MILLION)
TABLE 319 NORTH AMERICA: EPIGENETICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 320 EUROPE: EPIGENETICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 321 ASIA PACIFIC: EPIGENETICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 322 LATIN AMERICA: EPIGENETICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 323 MIDDLE EAST: EPIGENETICS MARKET FOR OTHER APPLICATIONS, BY REGION, 2024-2031 (USD MILLION)
TABLE 324 GCC COUNTRIES: EPIGENETICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 325 EPIGENETICS PRODUCTS MARKET, BY END USER, 2024-2031 (USD MILLION)
TABLE 326 EPIGENETICS PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2024-2031 (USD MILLION)
TABLE 327 NORTH AMERICA: EPIGENETICS PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 328 EUROPE: EPIGENETICS PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 329 ASIA PACIFIC: EPIGENETICS PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 330 LATIN AMERICA: EPIGENETICS PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 331 MIDDLE EAST: EPIGENETICS PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2024-2031 (USD MILLION)
TABLE 332 GCC COUNTRIES: EPIGENETICS PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 333 EPIGENETICS PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2024-2031 (USD MILLION)
TABLE 334 NORTH AMERICA: EPIGENETICS PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 335 EUROPE: EPIGENETICS PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 336 ASIA PACIFIC: EPIGENETICS PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 337 LATIN AMERICA: EPIGENETICS PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 338 MIDDLE EAST: EPIGENETICS PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2024-2031 (USD MILLION)
TABLE 339 GCC COUNTRIES: EPIGENETICS PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 340 EPIGENETICS PRODUCTS MARKET FOR HOSPITALS & CLINICS, BY REGION, 2024-2031 (USD MILLION)
TABLE 341 NORTH AMERICA: EPIGENETICS PRODUCTS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 342 EUROPE: EPIGENETICS PRODUCTS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 343 ASIA PACIFIC: EPIGENETICS PRODUCTS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 344 LATIN AMERICA: EPIGENETICS PRODUCTS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 345 MIDDLE EAST: EPIGENETICS PRODUCTS MARKET FOR HOSPITALS & CLINICS, BY REGION, 2024-2031 (USD MILLION)
TABLE 346 GCC COUNTRIES: EPIGENETICS PRODUCTS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 347 EPIGENETICS PRODUCTS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2024-2031 (USD MILLION)
TABLE 348 NORTH AMERICA: EPIGENETICS PRODUCTS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 349 EUROPE: EPIGENETICS PRODUCTS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 350 ASIA PACIFIC: EPIGENETICS PRODUCTS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 351 LATIN AMERICA: EPIGENETICS PRODUCTS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 352 MIDDLE EAST: EPIGENETICS PRODUCTS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2024-2031 (USD MILLION)
TABLE 353 GCC COUNTRIES: EPIGENETICS PRODUCTS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 354 EPIGENETICS SERVICES MARKET, BY END USER, 2024-2031 (USD MILLION)
TABLE 355 EPIGENETICS SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2024-2031 (USD MILLION)
TABLE 356 NORTH AMERICA: EPIGENETICS SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 357 EUROPE: EPIGENETICS SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 358 ASIA PACIFIC: EPIGENETICS SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 359 LATIN AMERICA: EPIGENETICS SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 360 MIDDLE EAST: EPIGENETICS SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2024-2031 (USD MILLION)
TABLE 361 GCC COUNTRIES: EPIGENETICS SERVICE MARKET PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 362 EPIGENETICS SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2024-2031 (USD MILLION)
TABLE 363 NORTH AMERICA: EPIGENETICS SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 364 EUROPE: EPIGENETICS SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 365 ASIA PACIFIC: EPIGENETICS SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 366 LATIN AMERICA: EPIGENETICS SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 367 MIDDLE EAST: EPIGENETICS SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2024-2031 (USD MILLION)
TABLE 368 GCC COUNTRIES: EPIGENETICS SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 369 EPIGENETICS SERVICES MARKET FOR HOSPITALS & CLINICS, BY REGION, 2024-2031 (USD MILLION)
TABLE 370 NORTH AMERICA: EPIGENETICS SERVICES MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 371 EUROPE: EPIGENETICS SERVICES MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 372 ASIA PACIFIC: EPIGENETICS SERVICES MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 373 LATIN AMERICA: EPIGENETICS SERVICES MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 374 MIDDLE EAST: EPIGENETICS SERVICES MARKET FOR HOSPITALS & CLINICS, BY REGION, 2024-2031 (USD MILLION)
TABLE 375 GCC COUNTRIES: EPIGENETICS SERVICES MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 376 EPIGENETICS MARKET, BY REGION, 2024-2031 (USD MILLION)
TABLE 377 NORTH AMERICA: EPIGENETICS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 378 NORTH AMERICA: EPIGENETICS MARKET, BY OFFERING, 2024-2031 (USD MILLION)
TABLE 379 NORTH AMERICA: EPIGENETICS PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 380 NORTH AMERICA: EPIGENETICS KITS & REAGENTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 381 NORTH AMERICA: EPIGENETICS ENZYMES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 382 NORTH AMERICA: EPIGENETICS SERVICES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 383 NORTH AMERICA: EPIGENETICS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
TABLE 384 NORTH AMERICA: EPIGENETICS MARKET, BY METHOD, 2024-2031 (USD MILLION)
TABLE 385 NORTH AMERICA: EPIGENETICS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
TABLE 386 NORTH AMERICA: EPIGENETICS PRODUCTS MARKET, BY END USER, 2024-2031 (USD MILLION)
TABLE 387 NORTH AMERICA: EPIGENETICS SERVICES MARKET, BY END USER, 2024-2031 (USD MILLION)
TABLE 388 US: EPIGENETICS MARKET, BY OFFERING, 2024-2031 (USD MILLION)
TABLE 389 US: EPIGENETICS PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 390 US: EPIGENETICS KITS & REAGENTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 391 US: EPIGENETICS ENZYMES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 392 US: EPIGENETICS SERVICES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 393 US: EPIGENETICS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
TABLE 394 US: EPIGENETICS MARKET, BY METHOD, 2024-2031 (USD MILLION)
TABLE 395 US: EPIGENETICS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
TABLE 396 US: EPIGENETICS PRODUCTS MARKET, BY END USER, 2024-2031 (USD MILLION)
TABLE 397 US: EPIGENETICS SERVICES MARKET, BY END USER, 2024-2031 (USD MILLION)
TABLE 398 CANADA: EPIGENETICS MARKET, BY OFFERING, 2024-2031 (USD MILLION)
TABLE 399 CANADA: EPIGENETICS PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 400 CANADA: EPIGENETICS KITS & REAGENTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 401 CANADA: EPIGENETICS ENZYMES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 402 CANADA: EPIGENETICS SERVICES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 403 CANADA: EPIGENETICS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
TABLE 404 CANADA: EPIGENETICS MARKET, BY METHOD, 2024-2031 (USD MILLION)
TABLE 405 CANADA: EPIGENETICS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
TABLE 406 CANADA: EPIGENETICS PRODUCTS MARKET, BY END USER, 2024-2031 (USD MILLION)
TABLE 407 CANADA: EPIGENETICS SERVICES MARKET, BY END USER, 2024-2031 (USD MILLION)
TABLE 408 EUROPE: EPIGENETICS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 409 EUROPE: EPIGENETICS MARKET, BY OFFERING, 2024-2031 (USD MILLION)
TABLE 410 EUROPE: EPIGENETICS PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 411 EUROPE: EPIGENETICS KITS & REAGENTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 412 EUROPE: EPIGENETICS ENZYMES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 413 EUROPE: EPIGENETICS SERVICES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 414 EUROPE: EPIGENETICS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
TABLE 415 EUROPE: EPIGENETICS MARKET, BY METHOD, 2024-2031 (USD MILLION)
TABLE 416 EUROPE: EPIGENETICS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
TABLE 417 EUROPE: EPIGENETICS PRODUCTS MARKET, BY END USER, 2024-2031 (USD MILLION)
TABLE 418 EUROPE: EPIGENETICS SERVICES MARKET, BY END USER, 2024-2031 (USD MILLION)
TABLE 419 GERMANY: EPIGENETICS MARKET, BY OFFERING, 2024-2031 (USD MILLION)
TABLE 420 GERMANY: EPIGENETICS PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 421 GERMANY: EPIGENETICS KITS & REAGENTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 422 GERMANY: EPIGENETICS ENZYMES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 423 GERMANY: EPIGENETICS SERVICES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 424 GERMANY: EPIGENETICS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
TABLE 425 GERMANY: EPIGENETICS MARKET, BY METHOD, 2024-2031 (USD MILLION)
TABLE 426 GERMANY: EPIGENETICS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
TABLE 427 GERMANY: EPIGENETICS PRODUCTS MARKET, BY END USER, 2024-2031 (USD MILLION)
TABLE 428 GERMANY: EPIGENETICS SERVICES MARKET, BY END USER, 2024-2031 (USD MILLION)
TABLE 429 UK: EPIGENETICS MARKET, BY OFFERING, 2024-2031 (USD MILLION)
TABLE 430 UK: EPIGENETICS PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 431 UK: EPIGENETICS KITS & REAGENTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 432 UK: EPIGENETICS ENZYMES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 433 UK: EPIGENETICS SERVICES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 434 UK: EPIGENETICS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
TABLE 435 UK: EPIGENETICS MARKET, BY METHOD, 2024-2031 (USD MILLION)
TABLE 436 UK: EPIGENETICS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
TABLE 437 UK: EPIGENETICS PRODUCTS MARKET, BY END USER, 2024-2031 (USD MILLION)
TABLE 438 UK: EPIGENETICS SERVICES MARKET, BY END USER, 2024-2031 (USD MILLION)
TABLE 439 FRANCE: EPIGENETICS MARKET, BY OFFERING, 2024-2031 (USD MILLION)
TABLE 440 FRANCE: EPIGENETICS PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 441 FRANCE: EPIGENETICS KITS & REAGENTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 442 FRANCE: EPIGENETICS ENZYMES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 443 FRANCE: EPIGENETICS SERVICES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 444 FRANCE: EPIGENETICS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
TABLE 445 FRANCE: EPIGENETICS MARKET, BY METHOD, 2024-2031 (USD MILLION)
TABLE 446 FRANCE: EPIGENETICS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
TABLE 447 FRANCE: EPIGENETICS PRODUCTS MARKET, BY END USER, 2024-2031 (USD MILLION)
TABLE 448 FRANCE: EPIGENETICS SERVICES MARKET, BY END USER, 2024-2031 (USD MILLION)
TABLE 449 ITALY: EPIGENETICS MARKET, BY OFFERING, 2024-2031 (USD MILLION)
TABLE 450 ITALY: EPIGENETICS PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 451 ITALY: EPIGENETICS KITS & REAGENTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 452 ITALY: EPIGENETICS ENZYMES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 453 ITALY: EPIGENETICS SERVICES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 454 ITALY: EPIGENETICS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
TABLE 455 ITALY: EPIGENETICS MARKET, BY METHOD, 2024-2031 (USD MILLION)
TABLE 456 ITALY: EPIGENETICS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
TABLE 457 ITALY: EPIGENETICS PRODUCTS MARKET, BY END USER, 2024-2031 (USD MILLION)
TABLE 458 ITALY: EPIGENETICS SERVICES MARKET, BY END USER, 2024-2031 (USD MILLION)
TABLE 459 SPAIN: EPIGENETICS MARKET, BY OFFERING, 2024-2031 (USD MILLION)
TABLE 460 SPAIN: EPIGENETICS PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 461 SPAIN: EPIGENETICS KITS & REAGENTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 462 SPAIN: EPIGENETICS ENZYMES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 463 SPAIN: EPIGENETICS SERVICES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 464 SPAIN: EPIGENETICS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
TABLE 465 SPAIN: EPIGENETICS MARKET, BY METHOD, 2024-2031 (USD MILLION)
TABLE 466 SPAIN: EPIGENETICS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
TABLE 467 SPAIN: EPIGENETICS PRODUCTS MARKET, BY END USER, 2024-2031 (USD MILLION)
TABLE 468 SPAIN: EPIGENETICS SERVICES MARKET, BY END USER, 2024-2031 (USD MILLION)
TABLE 469 REST OF EUROPE: EPIGENETICS MARKET, BY OFFERING, 2024-2031 (USD MILLION)
TABLE 470 REST OF EUROPE: EPIGENETICS PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 471 REST OF EUROPE: EPIGENETICS KITS & REAGENTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 472 REST OF EUROPE: EPIGENETICS ENZYMES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 473 REST OF EUROPE: EPIGENETICS SERVICES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 474 REST OF EUROPE: EPIGENETICS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
TABLE 475 REST OF EUROPE: EPIGENETICS MARKET, BY METHOD, 2024-2031 (USD MILLION)
TABLE 476 REST OF EUROPE: EPIGENETICS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
TABLE 477 REST OF EUROPE: EPIGENETICS PRODUCTS MARKET, BY END USER, 2024-2031 (USD MILLION)
TABLE 478 REST OF EUROPE: EPIGENETICS SERVICES MARKET, BY END USER, 2024-2031 (USD MILLION)
TABLE 479 ASIA PACIFIC: EPIGENETICS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 480 ASIA PACIFIC: EPIGENETICS MARKET, BY OFFERING, 2024-2031 (USD MILLION)
TABLE 481 ASIA PACIFIC: EPIGENETICS PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 482 ASIA PACIFIC: EPIGENETICS KITS & REAGENTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 483 ASIA PACIFIC: EPIGENETICS ENZYMES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 484 ASIA PACIFIC: EPIGENETICS SERVICES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 485 ASIA PACIFIC: EPIGENETICS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
TABLE 486 ASIA PACIFIC: EPIGENETICS MARKET, BY METHOD, 2024-2031 (USD MILLION)
TABLE 487 ASIA PACIFIC: EPIGENETICS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
TABLE 488 ASIA PACIFIC: EPIGENETICS PRODUCTS MARKET, BY END USER, 2024-2031 (USD MILLION)
TABLE 489 ASIA PACIFIC: EPIGENETICS SERVICES MARKET, BY END USER, 2024-2031 (USD MILLION)
TABLE 490 CHINA: EPIGENETICS MARKET, BY OFFERING, 2024-2031 (USD MILLION)
TABLE 491 CHINA: EPIGENETICS PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 492 CHINA: EPIGENETICS KITS & REAGENTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 493 CHINA: EPIGENETICS ENZYMES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 494 CHINA: EPIGENETICS SERVICES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 495 CHINA: EPIGENETICS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
TABLE 496 CHINA: EPIGENETICS MARKET, BY METHOD, 2024-2031 (USD MILLION)
TABLE 497 CHINA: EPIGENETICS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
TABLE 498 CHINA: EPIGENETICS PRODUCTS MARKET, BY END USER, 2024-2031 (USD MILLION)
TABLE 499 CHINA: EPIGENETICS SERVICES MARKET, BY END USER, 2024-2031 (USD MILLION)
TABLE 500 JAPAN: EPIGENETICS MARKET, BY OFFERING, 2024-2031 (USD MILLION)
TABLE 501 JAPAN: EPIGENETICS PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 502 JAPAN: EPIGENETICS KITS & REAGENTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 503 JAPAN: EPIGENETICS ENZYMES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 504 JAPAN: EPIGENETICS SERVICES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 505 JAPAN: EPIGENETICS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
TABLE 506 JAPAN: EPIGENETICS MARKET, BY METHOD, 2024-2031 (USD MILLION)
TABLE 507 JAPAN: EPIGENETICS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
TABLE 508 JAPAN: EPIGENETICS PRODUCTS MARKET, BY END USER, 2024-2031 (USD MILLION)
TABLE 509 JAPAN: EPIGENETICS SERVICES MARKET, BY END USER, 2024-2031 (USD MILLION)
TABLE 510 INDIA: EPIGENETICS MARKET, BY OFFERING, 2024-2031 (USD MILLION)
TABLE 511 INDIA: EPIGENETICS PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 512 INDIA: EPIGENETICS KITS & REAGENTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 513 INDIA: EPIGENETICS ENZYMES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 514 INDIA: EPIGENETICS SERVICES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 515 INDIA: EPIGENETICS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
TABLE 516 INDIA: EPIGENETICS MARKET, BY METHOD, 2024-2031 (USD MILLION)
TABLE 517 INDIA: EPIGENETICS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
TABLE 518 INDIA: EPIGENETICS PRODUCTS MARKET, BY END USER, 2024-2031 (USD MILLION)
TABLE 519 INDIA: EPIGENETICS SERVICES MARKET, BY END USER, 2024-2031 (USD MILLION)
TABLE 520 AUSTRALIA: EPIGENETICS MARKET, BY OFFERING, 2024-2031 (USD MILLION)
TABLE 521 AUSTRALIA: EPIGENETICS PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 522 AUSTRALIA: EPIGENETICS KITS & REAGENTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 523 AUSTRALIA: EPIGENETICS ENZYMES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 524 AUSTRALIA: EPIGENETICS SERVICES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 525 AUSTRALIA: EPIGENETICS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
TABLE 526 AUSTRALIA: EPIGENETICS MARKET, BY METHOD, 2024-2031 (USD MILLION)
TABLE 527 AUSTRALIA: EPIGENETICS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
TABLE 528 AUSTRALIA: EPIGENETICS PRODUCTS MARKET, BY END USER, 2024-2031 (USD MILLION)
TABLE 529 AUSTRALIA: EPIGENETICS SERVICES MARKET, BY END USER, 2024-2031 (USD MILLION)
TABLE 530 SOUTH KOREA: EPIGENETICS MARKET, BY OFFERING, 2024-2031 (USD MILLION)
TABLE 531 SOUTH KOREA: EPIGENETICS PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 532 SOUTH KOREA: EPIGENETICS KITS & REAGENTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 533 SOUTH KOREA: EPIGENETICS ENZYMES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 534 SOUTH KOREA: EPIGENETICS SERVICES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 535 SOUTH KOREA: EPIGENETICS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
TABLE 536 SOUTH KOREA: EPIGENETICS MARKET, BY METHOD, 2024-2031 (USD MILLION)
TABLE 537 SOUTH KOREA: EPIGENETICS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
TABLE 538 SOUTH KOREA: EPIGENETICS PRODUCTS MARKET, BY END USER, 2024-2031 (USD MILLION)
TABLE 539 SOUTH KOREA: EPIGENETICS SERVICES MARKET, BY END USER, 2024-2031 (USD MILLION)
TABLE 540 REST OF ASIA PACIFIC: EPIGENETICS MARKET, BY OFFERING, 2024-2031 (USD MILLION)
TABLE 541 REST OF ASIA PACIFIC: EPIGENETICS PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 542 REST OF ASIA PACIFIC: EPIGENETICS KITS & REAGENTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 543 REST OF ASIA PACIFIC: EPIGENETICS ENZYMES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 544 REST OF ASIA PACIFIC: EPIGENETICS SERVICES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 545 REST OF ASIA PACIFIC: EPIGENETICS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
TABLE 546 REST OF ASIA PACIFIC: EPIGENETICS MARKET, BY METHOD, 2024-2031 (USD MILLION)
TABLE 547 REST OF ASIA PACIFIC: EPIGENETICS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
TABLE 548 REST OF ASIA PACIFIC: EPIGENETICS PRODUCTS MARKET, BY END USER, 2024-2031 (USD MILLION)
TABLE 549 REST OF ASIA PACIFIC: EPIGENETICS SERVICES MARKET, BY END USER, 2024-2031 (USD MILLION)
TABLE 550 LATIN AMERICA: EPIGENETICS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 551 LATIN AMERICA: EPIGENETICS MARKET, BY OFFERING, 2024-2031 (USD MILLION)
TABLE 552 LATIN AMERICA: EPIGENETICS PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 553 LATIN AMERICA: EPIGENETICS KITS & REAGENTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 554 LATIN AMERICA: EPIGENETICS ENZYMES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 555 LATIN AMERICA: EPIGENETICS SERVICES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 556 LATIN AMERICA: EPIGENETICS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
TABLE 557 LATIN AMERICA: EPIGENETICS MARKET, BY METHOD, 2024-2031 (USD MILLION)
TABLE 558 LATIN AMERICA: EPIGENETICS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
TABLE 559 LATIN AMERICA: EPIGENETICS PRODUCTS MARKET, BY END USER, 2024-2031 (USD MILLION)
TABLE 560 LATIN AMERICA: EPIGENETICS SERVICES MARKET, BY END USER, 2024-2031 (USD MILLION)
TABLE 561 BRAZIL: EPIGENETICS MARKET, BY OFFERING, 2024-2031 (USD MILLION)
TABLE 562 BRAZIL: EPIGENETICS PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 563 BRAZIL: EPIGENETICS KITS & REAGENTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 564 BRAZIL: EPIGENETICS ENZYMES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 565 BRAZIL: EPIGENETICS SERVICES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 566 BRAZIL: EPIGENETICS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
TABLE 567 BRAZIL: EPIGENETICS MARKET, BY METHOD, 2024-2031 (USD MILLION)
TABLE 568 BRAZIL: EPIGENETICS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
TABLE 569 BRAZIL: EPIGENETICS PRODUCTS MARKET, BY END USER, 2024-2031 (USD MILLION)
TABLE 570 BRAZIL: EPIGENETICS SERVICES MARKET, BY END USER, 2024-2031 (USD MILLION)
TABLE 571 MEXICO: EPIGENETICS MARKET, BY OFFERING, 2024-2031 (USD MILLION)
TABLE 572 MEXICO: EPIGENETICS PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 573 MEXICO: EPIGENETICS KITS & REAGENTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 574 MEXICO: EPIGENETICS ENZYMES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 575 MEXICO: EPIGENETICS SERVICES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 576 MEXICO: EPIGENETICS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
TABLE 577 MEXICO: EPIGENETICS MARKET, BY METHOD, 2024-2031 (USD MILLION)
TABLE 578 MEXICO: EPIGENETICS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
TABLE 579 MEXICO: EPIGENETICS PRODUCTS MARKET, BY END USER, 2024-2031 (USD MILLION)
TABLE 580 MEXICO: EPIGENETICS SERVICES MARKET, BY END USER, 2024-2031 (USD MILLION)
TABLE 581 REST OF LATIN AMERICA: EPIGENETICS MARKET, BY OFFERING, 2024-2031 (USD MILLION)
TABLE 582 REST OF LATIN AMERICA: EPIGENETICS PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 583 REST OF LATIN AMERICA: EPIGENETICS KITS & REAGENTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 584 REST OF LATIN AMERICA: EPIGENETICS ENZYMES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 585 REST OF LATIN AMERICA: EPIGENETICS SERVICES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 586 REST OF LATIN AMERICA: EPIGENETICS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
TABLE 587 REST OF LATIN AMERICA: EPIGENETICS MARKET, BY METHOD, 2024-2031 (USD MILLION)
TABLE 588 REST OF LATIN AMERICA: EPIGENETICS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
TABLE 589 REST OF LATIN AMERICA: EPIGENETICS PRODUCTS MARKET, BY END USER, 2024-2031 (USD MILLION)
TABLE 590 REST OF LATIN AMERICA: EPIGENETICS SERVICES MARKET, BY END USER, 2024-2031 (USD MILLION)
TABLE 591 MIDDLE EAST: EPIGENETICS MARKET, BY REGION, 2024-2031 (USD MILLION)
TABLE 592 MIDDLE EAST: EPIGENETICS MARKET, BY OFFERING, 2024-2031 (USD MILLION)
TABLE 593 MIDDLE EAST: EPIGENETICS PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 594 MIDDLE EAST: EPIGENETICS KITS & REAGENTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 595 MIDDLE EAST: EPIGENETICS ENZYMES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 596 MIDDLE EAST: EPIGENETICS SERVICES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 597 MIDDLE EAST: EPIGENETICS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
TABLE 598 MIDDLE EAST: EPIGENETICS MARKET, BY METHOD, 2024-2031 (USD MILLION)
TABLE 599 MIDDLE EAST: EPIGENETICS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
TABLE 600 MIDDLE EAST: EPIGENETICS PRODUCTS MARKET, BY END USER, 2024-2031 (USD MILLION)
TABLE 601 MIDDLE EAST: EPIGENETICS SERVICES MARKET, BY END USER, 2024-2031 (USD MILLION)
TABLE 602 GCC COUNTRIES: EPIGENETICS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 603 GCC COUNTRIES: EPIGENETICS MARKET, BY OFFERING, 2024-2031 (USD MILLION)
TABLE 604 GCC COUNTRIES: EPIGENETICS PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 605 GCC COUNTRIES: EPIGENETICS KITS & REAGENTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 606 GCC COUNTRIES: EPIGENETICS ENZYMES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 607 GCC COUNTRIES: EPIGENETICS SERVICES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 608 GCC COUNTRIES: EPIGENETICS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
TABLE 609 GCC COUNTRIES: EPIGENETICS MARKET, BY METHOD, 2024-2031 (USD MILLION)
TABLE 610 GCC COUNTRIES: EPIGENETICS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
TABLE 611 GCC COUNTRIES: EPIGENETICS PRODUCTS MARKET, BY END USER, 2024-2031 (USD MILLION)
TABLE 612 GCC COUNTRIES: EPIGENETICS SERVICES MARKET, BY END USER, 2024-2031 (USD MILLION)
TABLE 613 SAUDI ARABIA: EPIGENETICS MARKET, BY OFFERING, 2024-2031 (USD MILLION)
TABLE 614 SAUDI ARABIA: EPIGENETICS PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 615 SAUDI ARABIA: EPIGENETICS KITS & REAGENTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 616 SAUDI ARABIA: EPIGENETICS ENZYMES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 617 SAUDI ARABIA: EPIGENETICS SERVICES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 618 SAUDI ARABIA: EPIGENETICS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
TABLE 619 SAUDI ARABIA: EPIGENETICS MARKET, BY METHOD, 2024-2031 (USD MILLION)
TABLE 620 SAUDI ARABIA: EPIGENETICS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
TABLE 621 SAUDI ARABIA: EPIGENETICS PRODUCTS MARKET, BY END USER, 2024-2031 (USD MILLION)
TABLE 622 SAUDI ARABIA: EPIGENETICS SERVICES MARKET, BY END USER, 2024-2031 (USD MILLION)
TABLE 623 UAE: EPIGENETICS MARKET, BY OFFERING, 2024-2031 (USD MILLION)
TABLE 624 UAE: EPIGENETICS PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 625 UAE: EPIGENETICS KITS & REAGENTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 626 UAE: EPIGENETICS ENZYMES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 627 UAE: EPIGENETICS SERVICES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 628 UAE: EPIGENETICS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
TABLE 629 UAE: EPIGENETICS MARKET, BY METHOD, 2024-2031 (USD MILLION)
TABLE 630 UAE: EPIGENETICS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
TABLE 631 UAE: EPIGENETICS PRODUCTS MARKET, BY END USER, 2024-2031 (USD MILLION)
TABLE 632 UAE: EPIGENETICS SERVICES MARKET, BY END USER, 2024-2031 (USD MILLION)
TABLE 633 REST OF GCC COUNTRIES: EPIGENETICS MARKET, BY OFFERING, 2024-2031 (USD MILLION)
TABLE 634 REST OF GCC COUNTRIES: EPIGENETICS PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 635 REST OF GCC COUNTRIES: EPIGENETICS KITS & REAGENTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 636 REST OF GCC COUNTRIES: EPIGENETICS ENZYMES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 637 REST OF GCC COUNTRIES: EPIGENETICS SERVICES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 638 REST OF GCC COUNTRIES: EPIGENETICS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
TABLE 639 REST OF GCC COUNTRIES: EPIGENETICS MARKET, BY METHOD, 2024-2031 (USD MILLION)
TABLE 640 REST OF GCC COUNTRIES: EPIGENETICS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
TABLE 641 REST OF GCC COUNTRIES: EPIGENETICS PRODUCTS MARKET, BY END USER, 2024-2031 (USD MILLION)
TABLE 642 REST OF GCC COUNTRIES: EPIGENETICS SERVICES MARKET, BY END USER, 2024-2031 (USD MILLION)
TABLE 643 REST OF MIDDLE EAST: EPIGENETICS MARKET, BY OFFERING, 2024-2031 (USD MILLION)
TABLE 644 REST OF MIDDLE EAST: EPIGENETICS PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 645 REST OF MIDDLE EAST: EPIGENETICS KITS & REAGENTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 646 REST OF MIDDLE EAST: EPIGENETICS ENZYMES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 647 REST OF MIDDLE EAST: EPIGENETICS SERVICES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 648 REST OF MIDDLE EAST: EPIGENETICS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
TABLE 649 REST OF MIDDLE EAST: EPIGENETICS MARKET, BY METHOD, 2024-2031 (USD MILLION)
TABLE 650 REST OF MIDDLE EAST: EPIGENETICS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
TABLE 651 EST OF MIDDLE EAST: EPIGENETICS PRODUCTS MARKET, BY END USER, 2024-2031 (USD MILLION)
TABLE 652 REST OF MIDDLE EAST: EPIGENETICS SERVICES MARKET, BY END USER, 2024-2031 (USD MILLION)
TABLE 653 AFRICA: EPIGENETICS MARKET, BY OFFERING, 2024-2031 (USD MILLION)
TABLE 654 AFRICA: EPIGENETICS PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 655 AFRICA: EPIGENETICS KITS & REAGENTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 656 AFRICA: EPIGENETICS ENZYMES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 657 AFRICA: EPIGENETICS SERVICES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 658 AFRICA: EPIGENETICS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
TABLE 659 AFRICA: EPIGENETICS MARKET, BY METHOD, 2024-2031 (USD MILLION)
TABLE 660 AFRICA: EPIGENETICS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
TABLE 661 AFRICA: EPIGENETICS PRODUCTS MARKET, BY END USER, 2024-2031 (USD MILLION)
TABLE 662 AFRICA: EPIGENETICS SERVICES MARKET, BY END USER, 2024-2031 (USD MILLION)
TABLE 663 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN EPIGENETICS MARKET, JANUARY 2023-MAY 2026
TABLE 664 EPIGENETICS MARKET: DEGREE OF COMPETITION
TABLE 665 EPIGENETICS MARKET: REGION FOOTPRINT
TABLE 666 EPIGENETICS MARKET: PRODUCT FOOTPRINT
TABLE 667 EPIGENETICS MARKET: SERVICE FOOTPRINT
TABLE 668 EPIGENETICS MARKET: METHOD FOOTPRINT
TABLE 669 EPIGENETICS MARKET: DETAILED LIST OF KEY STARTUPS/SMES
TABLE 670 EPIGENETICS MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
TABLE 671 EPIGENETICS MARKET: PRODUCT/SERVICE LAUNCHES, JANUARY 2023-MAY 2026
TABLE 672 EPIGENETICS MARKET: DEALS, JANUARY 2023-MAY 2026
TABLE 673 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
TABLE 674 THERMO FISHER SCIENTIFIC INC.: PRODUCTS/SERVICES OFFERED
TABLE 675 THERMO FISHER SCIENTIFIC INC.: PRODUCT LAUNCHES, JANUARY 2023-MAY 2026
TABLE 676 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2023-MAY 2026
TABLE 677 ILLUMINA, INC.: COMPANY OVERVIEW
TABLE 678 ILLUMINA, INC.: PRODUCTS/SERVICES OFFERED
TABLE 679 ILLUMINA, INC.: PRODUCT LAUNCHES, JANUARY 2023-MAY 2026
TABLE 680 ILLUMINA, INC.: DEALS, JANUARY 2023-MAY 2026
TABLE 681 MERCK KGAA: COMPANY OVERVIEW
TABLE 682 MERCK KGAA: PRODUCTS/SERVICES OFFERED
TABLE 683 DANAHER CORPORATION: COMPANY OVERVIEW
TABLE 684 DANAHER CORPORATION: PRODUCTS/SERVICES OFFERED
TABLE 685 DANAHER CORPORATION: DEALS, JANUARY 2023-MAY 2026
TABLE 686 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW
TABLE 687 BIO-RAD LABORATORIES, INC.: PRODUCTS/SERVICES OFFERED
TABLE 688 REVVITY: COMPANY OVERVIEW
TABLE 689 REVVITY: PRODUCTS/SERVICES OFFERED
TABLE 690 PACBIO: COMPANY OVERVIEW
TABLE 691 PACBIO: PRODUCTS/SERVICES OFFERED
TABLE 692 PACBIO: PRODUCT LAUNCHES, JANUARY 2023-MAY 2026
TABLE 693 PACBIO: DEALS, JANUARY 2023-MAY 2026
TABLE 694 ACTIVE MOTIF, INC.: COMPANY OVERVIEW
TABLE 695 ACTIVE MOTIF, INC.: PRODUCTS/SERVICES OFFERED
TABLE 696 ACTIVE MOTIF, INC.: DEALS, JANUARY 2023-MAY 2026
TABLE 697 NEW ENGLAND BIOLABS: COMPANY OVERVIEW
TABLE 698 NEW ENGLAND BIOLABS: PRODUCTS/SERVICES OFFERED
TABLE 699 NEW ENGLAND BIOLABS: PRODUCT LAUNCHES, JANUARY 2023-MAY 2026
TABLE 700 NEW ENGLAND BIOLABS: DEALS, JANUARY 2023-MAY 2026
TABLE 701 QIAGEN: COMPANY OVERVIEW
TABLE 702 QIAGEN: PRODUCTS/SERVICES OFFERED
TABLE 703 QIAGEN: PRODUCT LAUNCHES, JANUARY 2023-MAY 2026
TABLE 704 ZYMO RESEARCH CORPORATION: COMPANY OVERVIEW
TABLE 705 ZYMO RESEARCH CORPORATION: PRODUCTS/SERVICES OFFERED
TABLE 706 ZYMO RESEARCH CORPORATION: PRODUCT LAUNCHES, JANUARY 2023-MAY 2026
TABLE 707 ZYMO RESEARCH CORPORATION: DEALS, JANUARY 2023-MAY 2026
TABLE 708 HOLOGIC DIAGENODE: COMPANY OVERVIEW
TABLE 709 HOLOGIC DIAGENODE: PRODUCTS/SERVICES OFFERED
TABLE 710 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW
TABLE 711 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS/SERVICES OFFERED
TABLE 712 PROMEGA CORPORATION: COMPANY OVERVIEW
TABLE 713 PROMEGA CORPORATION: PRODUCTS/SERVICES OFFERED
TABLE 714 EPIGENTEK GROUP INC.: COMPANY OVERVIEW
TABLE 715 EPIGENTEK GROUP INC.: PRODUCTS/SERVICES OFFERED
TABLE 716 EPIGENTEK GROUP INC.: PRODUCT LAUNCHES, JANUARY 2023-MAY 2026
TABLE 717 EPICYPHER: COMPANY OVERVIEW
TABLE 718 FIOS GENOMICS: COMPANY OVERVIEW
TABLE 719 GENOMESCAN: COMPANY OVERVIEW
TABLE 720 CREATIVE BIOGENE: COMPANY OVERVIEW
TABLE 721 BPS BIOSCIENCE, INC.: COMPANY OVERVIEW
TABLE 722 ABNOVA CORPORATION: COMPANY OVERVIEW
TABLE 723 CREATIVE DIAGNOSTICS: COMPANY OVERVIEW
TABLE 724 BIOMODAL: COMPANY OVERVIEW
TABLE 725 10X GENOMICS: COMPANY OVERVIEW
TABLE 726 NOVOGENE CO., LTD.: COMPANY OVERVIEW
TABLE 727 IMPACT ANALYSIS OF SUPPLY-SIDE AND DEMAND-SIDE FACTORS
TABLE 728 RISK ASSESSMENT

List of Figures

FIGURE 1 EPIGENETICS MARKET SEGMENTATION
FIGURE 2 EPIGENETICS MARKET: REGIONAL SCOPE
FIGURE 3 EPIGENETICS MARKET: YEARS CONSIDERED
FIGURE 4 MARKET SCENARIO
FIGURE 5 GLOBAL EPIGENETICS MARKET, 2024-2031
FIGURE 6 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN EPIGENETICS MARKET, 2023-2026
FIGURE 7 DISRUPTIONS INFLUENCING GROWTH OF EPIGENETICS MARKET
FIGURE 8 HIGH-GROWTH SEGMENTS IN EPIGENETICS MARKET, 2026-2031
FIGURE 9 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN EPIGENETICS MARKET DURING FORECAST PERIOD
FIGURE 10 GROWING EMPHASIS ON POPULATION SCREENING PROGRAMS TO DRIVE MARKET
FIGURE 11 DNA METHYLATION ACCOUNTED FOR LARGEST SHARE OF EPIGENETICS MARKET IN NORTH AMERICA IN 2025
FIGURE 12 ASIA PACIFIC COUNTRIES TO REGISTER HIGHER GROWTH DURING FORECAST PERIOD
FIGURE 13 PRODUCTS TO DOMINATE MARKET DURING FORECAST PERIOD
FIGURE 14 EPIGENETICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 15 EPIGENETICS MARKET: PORTER'S FIVE FORCES ANALYSIS
FIGURE 16 EPIGENETICS MARKET: VALUE CHAIN ANALYSIS
FIGURE 17 EPIGENETICS MARKET: ECOSYSTEM ANALYSIS
FIGURE 18 EPIGENETICS MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
FIGURE 19 INVESTMENT AND FUNDING SCENARIO, 2023-2026
FIGURE 20 PATENT APPLICATIONS IN EPIGENETICS MARKET, JANUARY 2015-DECEMBER 2025
FIGURE 21 IMPACT OF AI/GEN AI ON EPIGENETICS MARKET
FIGURE 22 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT & SERVICE
FIGURE 23 KEY BUYING CRITERIA, BY END USER
FIGURE 24 EPIGENETICS MARKET, BY PRODUCT, 2024-2031 (MILLION UNITS)
FIGURE 25 NORTH AMERICA: EPIGENETICS MARKET SNAPSHOT
FIGURE 26 ASIA PACIFIC: EPIGENETICS MARKET SNAPSHOT
FIGURE 27 REVENUE ANALYSIS OF KEY PLAYERS IN EPIGENETICS MARKET, 2021-2025
FIGURE 28 EPIGENETICS MARKET SHARE ANALYSIS, 2025
FIGURE 29 EPIGENETICS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025
FIGURE 30 EPIGENETICS MARKET: COMPANY FOOTPRINT
FIGURE 31 EPIGENETICS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025
FIGURE 32 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
FIGURE 33 EV/EBITDA OF KEY VENDORS
FIGURE 34 EPIGENETICS MARKET: BRAND COMPARATIVE ANALYSIS
FIGURE 35 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2025)
FIGURE 36 ILLUMINA, INC.: COMPANY SNAPSHOT (2025)
FIGURE 37 MERCK KGAA: COMPANY SNAPSHOT (2025)
FIGURE 38 DANAHER CORPORATION: COMPANY SNAPSHOT (2025)
FIGURE 39 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2025)
FIGURE 40 REVVITY: COMPANY SNAPSHOT (2025)
FIGURE 41 PACBIO: COMPANY SNAPSHOT (2025)
FIGURE 42 QIAGEN: COMPANY SNAPSHOT (2025)
FIGURE 43 HOLOGIC DIAGENODE: COMPANY SNAPSHOT (2025)
FIGURE 44 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2025)
FIGURE 45 EPIGENETICS MARKET: RESEARCH DESIGN
FIGURE 46 EPIGENETICS MARKET: BREAKDOWN OF PRIMARIES
FIGURE 47 EPIGENETICS MARKET: INSIGHTS FROM PRIMARIES
FIGURE 48 GLOBAL EPIGENETICS MARKET ESTIMATION, 2025
FIGURE 49 EPIGENETICS MARKET: COMPANY REVENUE ANALYSIS-BASED ESTIMATION (BOTTOM-UP APPROACH), 2025
FIGURE 50 ILLUSTRATIVE EXAMPLE OF THERMO FISHER SCIENTIFIC INC.: REVENUE ANALYSIS (2025)
FIGURE 51 SEGMENTAL MARKET SIZE ESTIMATION: TOP-DOWN APPROACH
FIGURE 52 EPIGENETICS MARKET: CAGR PROJECTIONS
FIGURE 53 EPIGENETICS MARKET: DATA TRIANGULATION